-1 	|BT| (S (NP (NN Notch-1) (NN Notch-4) (JJ potent) (NN breast) (NN oncogene)) (VP (VBN overexpressed) (NP (JJ triple-negative) (NNS subtypes) (NN breast) (NN cancer)))) |ET| |BS|9:G05.360.340.024.340.375.500 10:A01.236|ES| 18:1 19:1 20:1 21:1 22:1 23:1 24:1 25:1 26:1 27:1
-1 	|BT| (S (NP (NP (ADVP (RB Surprisingly)) (, ,) (VBN given) (VBN proposed) (NN role) (NN loss) (NN function) (NN mutation) (NN p53) (NN gene) (NN development)) (NP (JJ human) (JJ colorectal) (NN cancer)) (, ,)) (VP (VBD found) (NP (NP (NN evidence)) (PP (CC either) (NP (NP (NN increase) (NN rate) (NN adenoma) (NN formation) (NN APC)) (CC +) (: /) (: -) (, ,) (NP (NN p53) (: -)) (: /) (FRAG (: -) (NP (NP (NN animal)) (, ,) (NP (NP (VBD increased) (NN rate) (NN progression) (NN malignancy)) (VP (VBN compared) (NP (NP (NN APC)) (NP (CC +) (: /) (: -) (NN p53) (CC +) (FRAG (: /) (CC +) (NP (NN mouse)))))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 13:D01.339.387 14:F01.525 15:F01.829.316.616 16:C23.550.291.656 17:C04.557.470.035 18:G05.365.590 19:B01.050 20:G03.495|ES| 2:1 9:1 11:1 12:1 17:1 18:1 19:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1
-1 	|BT| (S (NP (NNS Tumors)) (VP (VBD graded) (NP (NP (NN histology) (JJ immunostained) (NN p53)) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli)) (, ,) (NP (NN beta-catenin)) (, ,) (NP (NP (NP (NN cyclooxygenase-2) (-LRB- -LRB-) (NN Cox-2) (-RRB- -RRB-) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN iNOS)) (-RRB- -RRB-))) (VBN sequenced) (NN p53) (NN mutation))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 8:C04 18:G05.365.590 21:G05.360.340.024.340.375.249.050 22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 28:H01.158.100.656|ES| 2:1 10:1 12:1 14:1 19:1 34:1 53:1 54:1 55:1 56:1 57:1 58:1 59:1 60:1 61:1 62:1 63:1 64:1 65:1 66:1 67:1 68:1
-1 	|BT| (S (NP (DT A) (NN TRAMP/COX) (CD -2) (JJ knockout) (NN mouse) (NN model)) (ADVP (RB also)) (VP (VBD generated) (VP (VB determine) (NP (NN effect) (NN loss) (NN COX-2) (NN gene) (NN prostate) (NN tumorigenesis) (NN TRAMP) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 34:A05.360.444.575|ES| 5:1 9:1 19:1 32:1 52:1 69:1 70:1 71:1 72:1 73:1 74:1 75:1 76:1 77:1 78:1 79:1
-1 	|BT| (NP (NP (JJ Aberrant) (NN methylation) (NN SPARC) (NN gene) (NN promoter) (JJ clinical) (NN implication) (JJ gastric) (NN cancer))) |ET| |BS|35:G02.111.570.080.689.675 36:G02.111.087.029.538 37:D12.776.157.125.715|ES| 9:1 18:1 19:1 80:1 81:1 82:1 83:1 84:1 85:1 86:1
-1 	|BT| (NP (NP (NP (NN Activation) (JJ p53-dependent) (NN apoptosis) (JJ acute) (NN ablation) (NN glycogen) (NN synthase) (NN kinase-3beta)) (NP (JJ colorectal) (NN cancer) (NN cell)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11|ES| 17:1 18:1 19:1 66:1 87:1 88:1 89:1 90:1 91:1 92:1 93:1 94:1
-1 	|BT| (S (NP (JJ Aldo-keto) (NN reductase) (NN family) (CD 1) (NN B10) (NN gene) (NN silencing)) (VP (VBP result) (NP (NP (NN growth) (NN inhibition) (JJ colorectal) (NN cancer) (NN cell)) (: :) (NP (NP (NN Implication) (NN cancer)) (NN intervention))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 42:G05.355.315.203.374 43:F01.145.544 44:F01.829.263 45:G07.700.320.249|ES| 9:1 17:1 18:1 19:1 94:1 95:1 96:1 97:1 98:1 99:1 100:1 101:1 102:1 103:1 104:1 105:1 106:1
-1 	|BT| (FRAG (SBAR (IN Although) (S (NP (JJ incomplete) (JJ intestinal) (NN metaplasia)) (ADVP (RB morphologically)) (VP (VBZ resembles) (NP (NP (NN colon)) (, ,) (NP (NN CDX2) (NN expression))) (NP (ADJP (RB apparently) (JJR lower)) (JJ normal) (NN colon)))))) |ET| |BS|46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589|ES| 2:1 19:1 107:1 108:1 109:1 110:1 111:1 112:1 113:1 114:1 115:1 116:1 117:1 118:1
-1 	|BT| (S (NP (NN Analysis) (JJ colorectal) (NN cancer) (NN patient) (NN cohort)) (VP (VBZ establishes) (SBAR (S (NP (NN HNF4alpha)) (ADVP (RB significantly)) (VP (VBD upregulated) (NP (VBN compared) (NP (JJ adjacent) (JJ normal) (JJ epithelial) (NN resection)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 49:E05.318.760.500.750 50:M01.643|ES| 17:1 18:1 19:1 50:1 118:1 119:1 120:1 121:1 122:1 123:1 124:1 125:1 126:1 127:1 128:1
-1 	|BT| (S (NP (NN Animal) (NN breast) (NN colon) (NN tumor) (NN therapy) (NN study)) (VP (VBD showed) (SBAR (S (NP (JJ 15-PGDH) (NN gene) (NN therapy)) (VP (VBD produced) (NP (JJ significant) (NN delay) (NN 2LMP) (NN LS174T) (NN tumor) (NN growth))))))) |ET| |BS|8:C04 10:A01.236 19:B01.050 45:G07.700.320.249 51:C04.588.274.476.411.307.180 52:E02|ES| 7:1 9:1 19:1 23:1 102:1 113:1 129:1 130:1 131:1 132:1 133:1 134:1 135:1 136:1 137:1 138:1
-1 	|BT| (S (NP (NN Antagonism) (NN miR-221) (NN miR-222)) (VP (VBZ reduces) (NP (NN growth) (NN colon) (NN tumor) (NN mouse) (NN colitis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 51:C04.588.274.476.411.307.180 53:C06.405.205.265|ES| 7:1 19:1 52:1 102:1 113:1 139:1 140:1 141:1 142:1 143:1
-1 	|BT| (S (NP (NP (JJ Antisense) (NNS oligodeoxynucleotides) (JJ human) (NN superoxide) (NN dismutase) (CD 2)) (CC and/or) (NP (JJ ectopic) (NN bcl-2) (NN overexpression))) (VP (VBD avoided) (NP (NP (NNS polyphenols)) (SBAR (S (NP (JJ chemoradiotherapy-induced) (JJ colorectal) (NN cancer) (NN elimination)) (VP (VBD showed) (NP (NP (JJ mangano-type) (NN superoxide) (NN dismutase) (NN Bcl-2) (JJ key) (NN target) (JJ molecular) (NN mechanism)) (VP (VBN activated) (NP (JJ combined) (NN application) (NN t-PTER) (NNP QUER)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 56:D02.455.426.559.389.657.715 57:D13.695.578.424.450 58:D08.811.682.881 59:E02.186.079|ES| 17:1 18:1 19:1 36:1 132:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:1 164:1 165:1 166:1 167:1
-1 	|BT| (FRAG (PP (IN As) (NP (NP (JJ incomplete) (JJ intestinal) (NN metaplasia)) (VP (VBN associated) (NP (NP (JJR higher) (NN risk) (JJ gastric) (NN cancer)) (, ,) (NP (JJR lower) (NN CDX2) (NN expression)) (VP (VBD compared) (NP (NP (JJ complete) (JJ intestinal) (NN metaplasia) (JJ normal) (NN colon) (NN epithelium)) (VP (VBN resolved) (NP (NP (JJ current) (NN contradiction) (JJ tumor-suppressive) (NN role)) (NN CDX2) (NN colon) (JJ high) (NN prevalence) (NN CDX2) (JJ intestinal) (NN metaplasia)))))))))) |ET| |BS|8:C04 15:F01.829.316.616 46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589 60:E05.318.308.985.525.750 61:E05.318.740.600.800 62:A10.272|ES| 2:1 18:1 19:1 31:1 50:1 86:1 108:1 109:1 110:1 113:1 114:1 115:1 117:1 118:1 168:1 169:1 170:1 171:1 172:1 173:1 174:1 175:1 176:1 177:1 178:1 179:1
-1 	|BT| (S (PP (IN As) (NP (JJ key) (NN molecule) (NN drive) (NN progression) (NN chemoresistance) (JJ gastrointestinal) (NN cancer))) (, ,) (NP (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN HER2)) (VP (VBP become) (NP (JJ efficacious) (NN drug) (NN target) (NN setting)))) |ET| |BS|16:C23.550.291.656 63:G05.360.340.024.340.375.500.791.295.305 64:D08.811.913.696.620.682.725.400.009.300 65:D08.811.913.696.620.682.725.400.009.400 66:F01.658.293 67:D26|ES| 2:1 10:1 14:1 18:1 19:1 48:1 102:1 159:1 160:1 168:1 180:1 181:1 182:1 183:1 184:1 185:1 186:1 187:1 188:1 189:1 190:1 191:1 192:1
-1 	|BT| (S (NP (NP (NP (NN Beta-catenin/T-cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN Tcf)) (-RRB- -RRB-))) (NN signaling)) (NP (RB constitutively) (JJ active) (NN majority) (JJ human) (JJ colorectal) (NN cancer)) (, ,) (VP (VBG accompanying) (NP (NN change) (NN Bcl-2) (NN expression)))) |ET| |BS|4:C04.588.274.476.411.307 23:D12.776.091.249 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 68:A11.118.637.555.567.569 69:G02.111.087.800|ES| 2:1 10:1 14:1 17:1 18:1 19:1 36:1 115:1 158:1 185:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1
-1 	|BT| (S (NP (NN CDX2) (NN expression)) (ADVP (RB progressively)) (VP (VBD decreased) (NP (NP (JJ human) (JJ gastric) (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN dysplasia) (NN cancer))))) |ET| |BS|47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875|ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 114:1 115:1 201:1 202:1 203:1
-1 	|BT| (S (NP (NN CDX2) (NN expression)) (ADVP (RB progressively)) (VP (VBD decreased) (NP (NP (JJ human) (JJ gastric) (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN dysplasia) (NN cancer))))) |ET| |BS|33:C04.697.098 47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875|ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 114:1 115:1 159:1 201:1 202:1 203:1 204:1 205:1 206:1 207:1
-1 	|BT| (S (NP (NN CDX2) (NN expression)) (VP (ADVP (RB significantly)) (VBD decreased) (NP (NP (JJ incomplete) (JJ intestinal) (NN metaplasia)) (, ,) (NP (VBP express) (NP (NP (JJ gastric) (NN mucin)) (PRN (-LRB- -LRB-) (NP (NN MUC5AC) (NN MUC6)) (-RRB- -RRB-))) (JJ intestinal) (NP (NP (NN mucin)) (PRN (-LRB- -LRB-) (NP (NN MUC2)) (-RRB- -RRB-)))) (, ,)) (VP (VBD compared) (NP (JJ complete) (JJ intestinal) (NN metaplasia))) (, ,) (S (VP (VBP express) (NP (NP (JJ intestinal) (NN mucin)) (PRN (-LRB- -LRB-) (NP (NN MUC2)) (-RRB- -RRB-))))))) |ET| |BS|47:A03.556.124 48:C23.550.589 71:D12.776.395.560.631 72:D12.776.395.560.631.100|ES| 2:1 10:1 14:1 19:1 50:1 86:1 108:1 109:1 110:1 114:1 115:1 124:1 172:1 202:1 208:1 209:1 210:1 211:1 212:1
-1 	|BT| (S (S (NP (NN Cdx2)) (VP (VBZ induces) (NP (NN differentiation) (JJ intestinal) (JJ epithelial) (NN cell) (NN vitro)))) (: ;) (S (ADVP (RB therefore)) (, ,) (VP (VBD sought) (VP (VB establish) (SBAR (IN whether) (S (NP (JJ causal) (NN relationship)) (VP (VBZ exists) (NP (NN Cdx2) (NN activation) (JJ intestinal) (NN metaplasia))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 48:C23.550.589 73:N05.715.350.200 74:G04.299.151 75:A11.436|ES| 2:1 19:1 94:1 109:1 110:1 127:1 213:1 214:1 215:1 216:1 217:1 218:1 219:1 220:1 221:1 222:1 223:1 224:1 225:1
-1 	|BT| (NP (NP (NP (NN CDX2)) (, ,) (NP (NP (JJ human) (NN homologue)) (NP (FW Drosophila) (FW caudal))) (, ,)) (NP (VBN mutated) (NN allele) (NN replication) (NN error) (JJ positive) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 76:B01.050.500.131.617.289.310.250 77:G05.360.340.024.340.030 78:G02.111.087.222|ES| 2:1 17:1 18:1 19:1 36:1 114:1 226:1 227:1 228:1 229:1 230:1 231:1 232:1 233:1
-1 	|BT| (S (NP (NP (NN CDX2)) (, ,) (NP (NN master) (NN regulator) (JJ intestinal) (NN phenotype)) (, ,)) (VP (VBN shown) (NP (NN play) (JJ tumor-suppressive) (NN role) (NN colon) (NN cancer)))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 51:C04.588.274.476.411.307.180 79:I03.450.642.693 80:G05.695|ES| 2:1 18:1 19:1 31:1 109:1 113:1 114:1 177:1 234:1 235:1 236:1 237:1 238:1
-1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (NP (NP (JJ Gastric) (NN expression) (NN Cdx2)) (ADJP (RB alone) (JJ sufficient))) (VP (VBP induce) (NP (JJ intestinal) (NN metaplasia) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 48:C23.550.589 70:A03.556.875.875|ES| 19:1 52:1 104:1 109:1 110:1 115:1 213:1 239:1 240:1 241:1 242:1 243:1
-1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (PP (IN In) (NP (JJ human) (NN CRC) (NN cell))) (, ,) (NP (NN miR-221) (NN miR-222)) (VP (VBP act) (NP (JJ positive) (NN feedback) (NN loop) (NN increase) (NN expression) (NN level) (NN RelA) (NN STAT3)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 55:B01.050.150.900.649.801.400.112.400.400 81:E02.095.465.425.400.330.050.400 82:D12.644.360.024.342.300 83:L01.143.283.425|ES| 2:1 19:1 36:1 40:1 94:1 104:1 115:1 140:1 141:1 233:1 239:1 244:1 245:1 246:1 247:1 248:1 249:1 250:1 251:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (UCP (PP (IN In) (NP (NN mouse))) (, ,) (NP (NP (NN fucosylation) (NN deficiency) (NN lead) (NN colitis) (NN adenocarcinoma)) (, ,) (NP (NN loss) (NN Notch) (NN activation)) (, ,) (NP (NN down-regulation) (NN Hes1))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 53:C06.405.205.265 84:C04.557.470.200.025 85:G02.111.087.225 86:D01.268.556.435 87:C18.654.521|ES| 2:1 19:1 32:1 52:1 104:1 143:1 225:1 239:1 244:1 252:1 253:1 254:1 255:1 256:1 257:1 258:1
-1 	|BT| (S (NP (JJ Correlated) (NN pattern)) (VP (VBN observed) (NP (NP (NN HNF4alpha) (NN Cdx2) (JJ several) (JJ experimental) (NN model) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line)) (: :) (NP (NP (NN xenograft) (JJ nude) (NN mouse)) (, ,) (NP (NN wound) (NN healing) (NN glucose) (NN starvation)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 89:G16.100.856.891 90:C18.654.521.750 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 94:A11.251.210 95:E05.599|ES| 2:1 18:1 19:1 36:1 52:1 72:1 94:1 104:1 113:1 123:1 213:1 259:1 260:1 261:1 262:1 263:1 264:1 265:1 266:1 267:1 268:1 269:1 270:1
-1 	|BT| (S (S (NP (NN CRC) (NN patient)) (VP (VBD decreased) (NP (NN level) (NN miR-195-5p) (NN tumor) (NN tissue))) (S (ADVP (RB significantly)) (VP (VBD shortened) (SBAR (S (NP (NN survival)) (VP (VBD revealed) (NP (NP (NP (NN TCGA) (NN colon) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NN COAD)) (-RRB- -RRB-))) (NN dataset) (NN CRC) (NN cohort))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 46:A03.556.124.526.356 50:M01.643 84:C04.557.470.200.025 96:I03.784 97:V02.302 98:A10|ES| 7:1 10:1 14:1 19:1 113:1 120:1 121:1 124:1 202:1 245:1 249:1 255:1 271:1 272:1 273:1 274:1 275:1 276:1 277:1 278:1
-1 	|BT| (S (S (VP (VBG Crossing) (NP (NP (NP (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN Delta14)) (: /) (CC +) (-RRB- -RRB-))) (NP (NP (NN mouse) (JJ prone) (JJ spontaneous) (JJ intestinal) (NN tumor) (NN development) (NN pCdx2-9LacZ)) (NP (JJ transgenic) (NN mouse) (S (VP (VBG containing) (NP (NN LacZ) (NN reporter) (NN control) (JJ 9.3-kb) (NN Cdx2) (NN promoter))))))))) (VP (VBD showed) (SBAR (S (NP (NN promoter) (NN segment)) (VP (VBZ contains) (NP (NP (NN sequence)) (VP (VBG recapitulating) (NP (NN decrease) (NN Cdx2) (NN expression) (JJ intestinal) (NN cancer))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 26:G02.111.570.080 99:B01.050.050.136.500 100:G05.360.340.024.686.545 101:C04.588.274.476.411 102:C04.588.274.476.411 103:G11.427.695.525|ES| 7:1 10:1 14:1 18:1 19:1 35:1 52:1 83:1 109:1 115:1 132:1 213:1 279:1 280:1 281:1 282:1 283:1 284:1 285:1 286:1 287:1 288:1 289:1 290:1 291:1 292:1 293:1 294:1 295:1
-1 	|BT| (S (NP (NN Downregulation) (NN miR-610)) (VP (VBZ promotes) (SBAR (S (NP (NN proliferation) (NN tumorigenicity)) (VP (VBZ activates) (NP (NN Wnt/beta-catenin) (NN signaling) (JJ human) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 105:G02.149.115.800.925|ES| 19:1 36:1 195:1 296:1 297:1 298:1 299:1 300:1 301:1 302:1 303:1 304:1
-1 	|BT| (S (NP (JJ Ectopic) (NN expression) (NN miR-139-5p) (NN colon) (NN cancer) (NN cell) (NN line)) (VP (ADVP (RB significantly)) (NP (VBD suppressed) (NP (NP (NN cell) (NN growth) (VBN evidenced) (NN cell) (NN viability) (NN assay)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.001)))) (-RRB- -RRB-))) (NP (NP (NP (NN colony) (NN formation) (NN assay)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-))) (NP (NP (NN xenograft) (NN tumor) (NN growth) (JJ nude) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-))))))) |ET| |BS|8:C04 20:G03.495 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 94:A11.251.210 106:E05.091 107:G05.355.315.202 108:G04.299.316 109:I01.696.116|ES| 7:1 10:1 14:1 18:1 19:1 43:1 52:1 94:1 102:1 113:1 115:1 124:1 264:1 265:1 266:1 305:1 306:1 307:1 308:1 309:1 310:1 311:1 312:1 313:1 314:1 315:1
-1 	|BT| (NP (NP (NN Expression) (JJ gut-enriched) (JJ Kruppel-like) (NN factor)) (FRAG (-LRB- -LRB-) (NP (NP (JJ Kruppel-like) (NN factor) (CD 4) (-RRB- -RRB-) (NN gene)) (JJ human) (ADJP (NN colon) (NN cancer) (NN cell) (NN line) (NN RKO) (JJ dependent)) (NN CDX2)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210|ES| 9:1 10:1 14:1 18:1 19:1 36:1 94:1 113:1 114:1 185:1 264:1 316:1 317:1 318:1 319:1 320:1 321:1
-1 	|BT| (S (NP (NN Expression) (NN KLK13) (NN KLK14) (NN gene)) (VP (VBN examined) (NP (NP (NN mRNA) (NN protein) (NN level) (NN cohort) (CD 57) (NN patient)) (NP (NP (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-)))))) |ET| |BS|6:G05.360.340.024.340 50:M01.643 110:C04.588.894.797.520.109.220.249 111:D13.444.735.544 112:D12.776.097.820|ES| 4:1 9:1 10:1 14:1 18:1 19:1 120:1 121:1 249:1 316:1 322:1 323:1 324:1 325:1 326:1 327:1 328:1 329:1
-1 	|BT| (S (NP (JJ Further) (NN decrease) (NN CDX2) (NN expression) (JJ gastric) (NN dysplasia) (NN cancer)) (VP (VBZ suggests) (NP (NP (NN CDX2) (NN play) (JJ similar) (JJ anticarcinogenic) (NN role)) (JJ intestinal) (NN metaplasia) (NN colon)))) |ET| |BS|15:F01.829.316.616 46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589 70:A03.556.875.875 79:I03.450.642.693|ES| 18:1 19:1 31:1 86:1 109:1 110:1 113:1 114:1 115:1 203:1 238:1 295:1 330:1 331:1 332:1 333:1
-1 	|BT| (FRAG (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ high) (NN uniform) (NN expression) (NN CDX2)) (NP (NP (JJ characteristic) (JJ metastatic) (JJ colorectal) (NN cancer)) (, ,) (NP (ADJP (ADJP (JJ weak)) (CC and/or) (ADJP (JJ focal))) (NN CDX2) (NN expression) (JJ alert) (JJ surgical) (NN pathologist) (NN possibility) (JJ primary) (NN lung) (NN adenocarcinoma)) (, ,) (NP (ADVP (RB especially)) (NN presence) (NN goblet) (NN cell) (NN morphology))))) |ET| |BS|113:C04.697.650 114:J01.637.215 115:E04|ES| 2:1 17:1 18:1 19:1 94:1 114:1 115:1 149:1 178:1 255:1 328:1 334:1 335:1 336:1 337:1 338:1 339:1 340:1 341:1 342:1 343:1 344:1 345:1 346:1 347:1 348:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN Cdx2)) (VP (VBD decreased) (S (VP (VBG knocking) (NP (NN HNF4alpha) (JJ human) (NN colon) (NN cancer) (NN cell)) (S (VP (VBG using) (NP (NN siRNA) (NN colon) (NN mouse))))))) (S (ADVP (RB conditionally)) (VP (VBD knocked) (NP (NN Hnf4alpha) (NN gene) (JJ adult) (NN intestine)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN Hnf4alpha)) (PRN (-LRB- -LRB-) (NP (NN f/f)) (-RRB- -RRB-))) (: ;) (NP (NNP VilCre) (-LRB- -LRB-) (NN ERT2) (-RRB- -RRB-) (NN mouse))) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 41:A11 46:A03.556.124.526.356 47:A03.556.124 55:B01.050.150.900.649.801.400.112.400.400 116:D08.811.913.696.620.682.700.567.249.750 117:D13.150.650.700 118:D01.248.497.158.380 119:M01.060.116|ES| 2:1 9:1 10:1 14:1 18:1 19:1 36:1 52:1 94:1 113:1 123:1 202:1 213:1 217:1 334:1 349:1 350:1 351:1 352:1 353:1 354:1 355:1 356:1 357:1 358:1 359:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ stable) (NN overexpression)) (VP (VBG using) (NP (JJ lentiviral) (NN vector) (NN NCI-H460) (NN A549) (NN cell)))) (VP (VBD inhibited) (NP (NN tumor) (NN xenograft) (NN growth) (JJ immunodeficient) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (ADJP (CD 50) (NN %)) (NN reduction)) (VP (VBN compared) (NP (NN control)) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-))) (, ,) (PP (IN whereas) (NP (NP (NP (NN effect) (NN mir-660) (NN overexpression) (JJ absent) (NN H1299)) (, ,) (NP (NP (NN lung) (NN cancer) (NN cell) (NN line)) (VP (VBG lacking) (NP (NN p53) (NN locus))))) (, ,) (NP (ADJP (FW vitro) (FW vivo)) (NN assay))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 11:B01.050.150.900.649.865.635.505.500 41:A11 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 94:A11.251.210 106:E05.091 120:I01.409.418.750.600.480.150 121:B04.820.650.589 122:C14.280.383 123:G05.360.337 124:C20.673|ES| 2:1 7:1 10:1 12:1 14:1 18:1 19:1 50:1 52:1 75:1 94:1 102:1 152:1 216:1 264:1 265:1 289:1 310:1 328:1 334:1 350:1 360:1 361:1 362:1 363:1 364:1 365:1 366:1 367:1 368:1 369:1 370:1 371:1 372:1 373:1 374:1 375:1 376:1 377:1 378:1
-1 	|BT| (S (NP (NN gamma-Secretase) (NN inhibitor)) (VP (VBP abrogate) (NP (NP (JJ oxaliplatin-induced) (NN activation) (NN Notch-1) (NN signaling) (NN pathway) (NN colon) (NN cancer) (NN cell)) (VP (VBG resulting) (NP (VBN enhanced) (NN chemosensitivity)))))) |ET| |BS|41:A11 69:G02.111.087.800 125:D08.811.277.656.300.032 126:G02.111.087.800|ES| 18:1 19:1 20:1 94:1 113:1 195:1 225:1 379:1 380:1 381:1 382:1 383:1 384:1 385:1 386:1
-1 	|BT| (NP (NP (NP (NN Germline) (JJ somatic) (NN mutation) (NN BER) (NN gene)) (, ,) (NP (NP (NN MutY) (NN Homolog)) (PRN (-LRB- -LRB-) (NP (NN MUTYH/MYH)) (-RRB- -RRB-))) (NP (NP (JJ DNA-directed) (NN polymerase)) (PRN (-LRB- -LRB-) (NP (NN POLB)) (-RRB- -RRB-))) (, ,)) (NP (VBN associated) (VBN increased) (NN risk) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 61:E05.318.740.600.800 127:D08.811.913.696.445.308.300 128:E02.095.301 129:G02.111.087.219 130:A05.360.490|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 34:1 47:1 169:1 171:1 387:1 388:1 389:1 390:1 391:1 392:1 393:1 394:1 395:1
-1 	|BT| (S (NP (NN HDAC8) (NN STAT3)) (VP (VBP repress) (NP (NN BMF) (NN gene) (NN activity) (NN colon) (NN cancer) (NN cell)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 41:A11 46:A03.556.124.526.356 82:D12.644.360.024.342.300|ES| 9:1 18:1 19:1 94:1 113:1 251:1 396:1 397:1 398:1 399:1
-1 	|BT| (NP (NP (ADJP (RB Here) (VBN studied)) (NN role) (NN HNF4alpha) (NN mechanism) (NN deregulation) (NN Cdx2) (NN colon) (NN cancer))) |ET| |BS|15:F01.829.316.616|ES| 18:1 19:1 31:1 113:1 123:1 162:1 213:1 400:1 401:1 402:1
-1 	|BT| (S (NP (ADJP (RB Here) (VBN investigated)) (NP (NN role) (NN Bcl-3) (NN azoxymethane/dextran) (NN sulfate) (NN sodium)) (PRN (-LRB- -LRB-) (NP (NN AOM/DSS)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (NP (NN colon) (NN tumor)) (, ,) (NP (NN mouse) (NN model) (JJ colitis-associated) (JJ colorectal) (NN cancer)) (JJ human)))) |ET| |BS|4:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 51:C04.588.274.476.411.307.180 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 131:D09.698.365.272.300 132:D02.172.080|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 31:1 36:1 52:1 72:1 113:1 400:1 403:1 404:1 405:1 406:1 407:1 408:1 409:1 410:1
-1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBD investigated) (NP (NP (NN cell) (NN death) (NN signaling) (NN mechanism)) (VP (VBD induced) (NP (NN PGG) (JJ human) (NN prostate) (NN cancer) (NN cell) (JJ different) (NN p53) (JJ functional) (NN status)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 133:D01.248.497.158.685.750.744.600 134:G04.299.139 135:C23.550.260|ES| 2:1 12:1 18:1 19:1 36:1 77:1 94:1 162:1 195:1 400:1 403:1 411:1 412:1 413:1 414:1 415:1 416:1
-1 	|BT| (FRAG (ADVP (RB Here)) (, ,) (NP (NP (NN report) (ADJP (RB inversely) (JJ related)) (NN expression) (NN miR-137) (NN CAR) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell)) (, ,) (SBAR (WHADVP (WRB wherein)) (S (NP (NN miR-137)) (VP (VBD downregulated) (NP (JJ resistant) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320 139:J01.937.500.100|ES| 2:1 19:1 94:1 115:1 400:1 417:1 418:1 419:1 420:1 421:1 422:1 423:1 424:1 425:1 426:1 427:1
-1 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBP show) (SBAR (S (NP (NNP NANOG)) (VP (VBD expressed) (NP (NP (NN NANOG1) (NN NANOGP8) (JJ human) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-)))))))) |ET| |BS|4:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 6:1 10:1 14:1 17:1 18:1 19:1 36:1 245:1 428:1 429:1 430:1 431:1 432:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NP (JJ molecular) (NN detail)) (VP (VBG underlying) (NP (NP (NN miR-146a) (JJ mediated) (NN regulation) (NN target) (NN gene) (JJ precise) (JJ biological) (NN function) (NN cancer)) (, ,) (NP (NP (RB especially) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) (VP (VBZ remains) (ADJP (JJ unclear)))) |ET| |BS|104:C04.557.470.200.025.255 140:G05.355.315 141:G16.100|ES| 2:1 9:1 10:1 14:1 18:1 19:1 33:1 160:1 161:1 303:1 304:1 345:1 433:1 434:1 435:1 436:1 437:1 438:1 439:1 440:1 441:1 442:1 443:1
-1 	|BT| (NP (NP (NP (NP (JJ Human) (NN CRC) (NN tissue)) (NP (JJR higher) (NN level) (NN miR-221) (NN miR-222) (JJ nontumor) (NN colon) (NN tissue))) (: ;) (NP (NN increase)) (VP (VBD correlated) (NP (VBN increased) (NN level) (NN RelA) (NN STAT3) (NNS mRNAs))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544|ES| 19:1 40:1 47:1 113:1 140:1 141:1 170:1 217:1 245:1 249:1 250:1 251:1 272:1 444:1 445:1 446:1 447:1
-1 	|BT| (S (NP (NN Hypermethylation) (NN miR-137) (NN promoter) (JJ negative) (NN regulation) (NN miR-137) (NN CAR)) (VP (VP (VBP contribute) (NP (NP (NN part)) (VP (VBD reduced) (NP (NN miR-137) (NN expression))))) (VP (VBD increased) (NP (NN CAR) (NN MDR1) (NN expression) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 142:I01.880.604|ES| 19:1 47:1 83:1 94:1 115:1 420:1 421:1 423:1 424:1 438:1 448:1 449:1 450:1 451:1 452:1 453:1
-1 	|BT| (NP (NP (NP (NN Immunohistochemistry) (NN beta-catenin)) (, ,) (NP (NN c-myc)) (, ,) (NP (NP (NN Ki-67) (NN TUNEL-staining)) (VP (VBN performed) (VP (VBP investigate) (NP (NP (NN TQ) (POS 's)) (NN effect) (JJ major) (JJ colorectal) (NN cancer) (NN pathway))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 143:E01.370.225.500.607.512 144:E05.393.475|ES| 2:1 17:1 18:1 19:1 60:1 75:1 383:1 454:1 455:1 456:1 457:1 458:1 459:1 460:1 461:1 462:1
-1 	|BT| (S (PP (IN In) (NP (JJ nude) (NN mouse) (NN xenograft) (NN model))) (, ,) (NP (NN overexpression) (NN miR-141) (NN knockdown) (NN MAP4K4)) (ADVP (RB significantly)) (VP (VBD repressed) (NP (JJ pancreatic) (NN cancer) (NN cell) (NN growth)))) |ET| |BS|41:A11 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875|ES| 2:1 18:1 19:1 52:1 72:1 94:1 102:1 124:1 152:1 244:1 265:1 266:1 463:1 464:1 465:1 466:1 467:1
-1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN PIM) (NN kinase)) (VP (VBP activate) (S (NP (NN MYC) (NN signaling) (NN mRNA) (NN translation) (NN prostate) (NN cancer)) (VP (VBP cooperate) (S (NP (NN MYC)) (VP (VB accelerate) (NP (NN tumorigenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 69:G02.111.087.800 145:G02.111.087.675.871|ES| 2:1 18:1 19:1 77:1 78:1 195:1 244:1 325:1 468:1 469:1 470:1 471:1 472:1 473:1 474:1 475:1
-1 	|BT| (S (PP (IN In) (NP (JJ current) (NN report))) (, ,) (VBN used) (S (NP (NN DLD-1) (JJ colorectal) (NN cancer) (NN cell)) (ADVP (RB stably)) (NP (VBN transfected) (NP (NN POX) (NN gene) (NN control) (JJ tetracycline-inducible) (NN promoter))) (VP (VBD found) (SBAR (S (NP (CD three) (NN pathway) (NN cross) (NN talk)) (VP (VBD downregulated) (NP (NP (NN POX)) (: :) (NP (NP (NP (NP (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (NN pathway)) (, ,) (NP (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN pathway) (NN Wnt/beta-catenin) (NN pathway)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 23:D12.776.091.249 24:D08.811.600.720.750 41:A11 64:D08.811.913.696.620.682.725.400.009.300 146:D02.455.426.559.847.562.900.875 147:G02.149.115.800.925 148:G12.425.143.281|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 37:1 61:1 76:1 83:1 94:1 102:1 104:1 175:1 184:1 185:1 186:1 187:1 244:1 289:1 302:1 383:1 417:1 426:1 476:1 477:1 478:1 479:1 480:1 481:1 482:1 483:1 484:1
-1 	|BT| (NP (NP (PP (IN In) (NP (JJ particular))) (, ,) (NP (NP (NN expression) (JJ intestine-specific) (NN transcription) (NN factor) (NN Cdx2)) (, ,) (NP (JJ key) (NN gene) (JJ intestinal) (NN identity)) (VP (VBD downregulated) (NP (NP (JJ invasive) (NN cancer) (NN cell)) (, ,) (VP (VBD reduced) (NP (NN wound) (NN healing) (NN vitro)))))))) |ET| |BS|41:A11 47:A03.556.124 89:G16.100.856.891 149:G05.360.340.024.340.364.875.890|ES| 2:1 9:1 18:1 19:1 94:1 109:1 115:1 159:1 185:1 213:1 216:1 244:1 267:1 268:1 426:1 452:1 485:1 486:1 487:1 488:1 489:1
-1 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NN colon) (NN cancer) (NN cell)) (VP (MD may) (VP (VB up-regulate) (NP (NN Notch-1) (JJ protective) (NN mechanism) (NN response) (NN chemotherapy))))) |ET| |BS|41:A11 150:Z01.542.248.960 151:E02.319|ES| 2:1 18:1 19:1 20:1 94:1 113:1 162:1 244:1 490:1 491:1 492:1 493:1 494:1 495:1
-1 	|BT| (FRAG (PP (IN In) (NP (JJ adult))) (, ,) (NP (NP (JJ Cdx1) (NN Cdx2)) (, ,) (NP (NN Cdx4)) (, ,) (NP (ADJP (RB intensively) (VBN explored)) (NN function) (JJ intestinal) (NN tissue) (NN homeostasis) (NN pathogenesis) (JJ gastrointestinal) (NN cancer)))) |ET| |BS|47:A03.556.124 98:A10 119:M01.060.116 152:G07.700.345|ES| 2:1 18:1 19:1 33:1 109:1 183:1 213:1 244:1 272:1 355:1 496:1 497:1 498:1 499:1 500:1 501:1
-1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBP demonstrate) (S (NP (NP (NP (NN histone) (NN deacetylase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN HDACi)) (-RRB- -RRB-))) (NN vorinostat) (NN LBH589)) (VP (ADVP (RB significantly)) (VBP downregulate) (NP (NN TS) (NN gene) (NN expression) (NN panel) (NN colon) (NN cancer) (NN cell) (NN line)))))) |ET| |BS|94:A11.251.210 153:D27.505.519.389.360 154:Z01.058.266.887 155:G05.355.310|ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 113:1 115:1 124:1 131:1 244:1 264:1 380:1 502:1 503:1 504:1 505:1 506:1 507:1 508:1 509:1 510:1
-1 	|BT| (FRAG (PP (IN In) (NP (NN study))) (, ,) (NP (VBN explored) (NN role) (NN miR-141) (JJ pancreatic) (NN cancer))) |ET| |BS|15:F01.829.316.616|ES| 2:1 18:1 19:1 31:1 131:1 244:1 463:1 467:1 499:1
-1 	|BT| (FRAG (NP (ADVP (FW In) (FW vitro)) (PRN (, ,) (NP (NP (VBN forced) (NN expression) (NN Cdx2) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line)) (SBAR (S (NP (VBN retarded) (NN wound) (NN repair)) (VP (VBD reduced) (NP (NN migration)))))) (, ,))) (SBAR (IN whereas) (S (NP (NN inhibition) (NN Cdx2) (NN expression) (NN RNA) (NN interference)) (VP (VBD enhanced) (NP (NN migration)))))) |ET| |BS|43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 89:G16.100.856.891 94:A11.251.210 122:C14.280.383 156:G05.355.315.203.374.790|ES| 2:1 18:1 19:1 36:1 94:1 103:1 113:1 115:1 213:1 216:1 244:1 264:1 267:1 372:1 385:1 452:1 511:1 512:1 513:1 514:1 515:1 516:1
-1 	|BT| (NP (NP (NP (NN Incubation) (NN CRC) (NN cell) (NN miR-221) (NN miR-222) (NN inhibitor)) (SBAR (S (NP (VBD reduced) (NN proliferation) (NN colony) (NN formation)) (VP (VBN compared) (NP (NN control) (NN cell))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 41:A11 109:I01.696.116|ES| 19:1 43:1 50:1 94:1 140:1 141:1 245:1 289:1 299:1 314:1 380:1 452:1 517:1
-1 	|BT| (NP (NP (ADVP (RB Interestingly)) (, ,) (NP (NP (NP (JJ gastric) (NN adenocarcinoma)) (ADJP (RB significantly) (JJ frequent)) (NN Pdx-1-Cre)) (: ;) (NP (NN Smad4) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NN Trp53) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NP (NP (NN Cdh1) (-LRB- -LRB-) (NN F) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (: /) (CC +) (-RRB- -RRB-))) (NN mouse) (NN Pdx-1-Cre)) (: ;) (NP (NN Smad4) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NN Trp53) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NN Cdh1) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-)) (NN mouse)) (, ,) (S (NP (VBG demonstrating) (NN Cdh1) (NN heterozygosity)) (VP (VBZ accelerates) (NP (NN development) (NN progression) (JJ gastric) (NN adenocarcinoma)))) (, ,) (NP (NN combination) (NN loss) (NN Smad4) (NN p53))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 70:A03.556.875.875 84:C04.557.470.200.025 118:D01.248.497.158.380 157:G05.380.383|ES| 2:1 10:1 12:1 14:1 19:1 32:1 35:1 48:1 51:1 52:1 86:1 124:1 217:1 255:1 518:1 519:1 520:1 521:1 522:1 523:1 524:1 525:1 526:1 527:1 528:1 529:1 530:1
-1 	|BT| (S (NP (JJ Intestinal) (NN metaplasia) (NN dysplasia) (JJ low) (NN expression) (NN CDX2)) (VP (MD may) (VP (VB serve) (NP (JJ predictive) (NN marker) (JJ gastric) (NN cancer))))) |ET| |BS|47:A03.556.124 48:C23.550.589 158:D23.101|ES| 18:1 19:1 86:1 110:1 114:1 115:1 203:1 204:1 491:1 531:1 532:1 533:1 534:1
-1 	|BT| (NP (NP (NN INTRODUCTION)) (: :) (NP (NP (NP (NP (JJ Triple) (JJ negative) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN TNBC)) (-RRB- -RRB-))) (NP (JJ aggressive) (ADJP (RB currently) (JJ specific)) (JJ therapeutic) (NN target))) (, ,) (NP (NP (NN hormone) (NN receptor) (JJ human) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN type) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN HER2)) (-RRB- -RRB-)))) (: ;) (ADVP (RB therefore)) (, ,) (NP (NN prognosis) (JJ poor))) |ET| |BS|52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 159:I01.880.735.634 160:C04.588.180.788 161:D06.472 162:F01.145.126.125 163:E01.789|ES| 2:1 10:1 14:1 18:1 19:1 23:1 36:1 102:1 104:1 148:1 160:1 184:1 185:1 186:1 188:1 217:1 218:1 449:1 535:1 536:1 537:1 538:1 539:1 540:1 541:1 542:1 543:1 544:1 545:1
-1 	|BT| (S (NP (NN K-Ras) (NN mutation) (NN treatment) (NN outcome) (JJ colorectal) (NN cancer) (NN patient)) (VP (VBG receiving) (NP (JJ exclusive) (NN fluoropyrimidine) (NN therapy)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800|ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1
-1 	|BT| (S (NP (NN LINE-1) (NN methylation)) (VP (VBD decreased) (SBAR (S (NP (NN transition) (JJ intestinal) (NN metaplasia) (JJ gastric) (NN adenoma) (NN decrease)) (VP (VBD occurred) (NP (NN transition) (JJ gastric) (NN adenoma) (NN GC))))))) |ET| |BS|17:C04.557.470.035 36:G02.111.087.029.538 47:A03.556.124 48:C23.550.589 70:A03.556.875.875|ES| 19:1 42:1 81:1 86:1 109:1 110:1 202:1 295:1 551:1 552:1 553:1 554:1
-1 	|BT| (S (NP (NP (ADJP (RB Little) (VBN known)) (JJ biological) (NN significance) (NN ELK1)) (, ,) (NP (JJ transcriptional) (NN factor))) (VP (VBZ activates) (NP (NP (JJ downstream) (NN target)) (PP (VBG including) (NP (NP (NN c-fos) (NN proto-oncogene)) (, ,) (NP (NN bladder) (NN cancer))))))) |ET| |BS|165:G05.360.340.024.340.375.500.791.330 166:D12.776.930 167:H01.158.273|ES| 2:1 18:1 19:1 160:1 185:1 301:1 440:1 555:1 556:1 557:1 558:1 559:1 560:1 561:1 562:1 563:1 564:1
-1 	|BT| (NP (NP (NNS METHODS) (: :)) (NP (NP (NP (NN CRC) (NN cell) (NN line)) (PRN (-LRB- -LRB-) (NP (NN HCT116) (NN RKO)) (-RRB- -RRB-))) (VP (VBN transfected) (S (NP (NN miR-221) (NN miR-222)) (VP (VBP mimic) (NP (NN inhibitor))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 94:A11.251.210 168:E05.581|ES| 10:1 14:1 19:1 94:1 104:1 140:1 141:1 245:1 264:1 320:1 380:1 479:1 565:1 566:1 567:1
-1 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (NN Notch) (NN status)) (VP (VBD analysed) (S (VP (VBG studying) (S (NP (NN expression) (NN Notch) (NN effector) (NN Hes1) (NN Notch) (NNS ligands/receptors)) (NP (JJ human) (JJ colorectal) (NP (NP (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NN mouse) (NN model) (NN Apc) (NN mutation)))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 168:E05.581 169:D12.776.543.750.725 170:D27.720.470.480|ES| 10:1 14:1 17:1 18:1 19:1 34:1 36:1 52:1 72:1 104:1 115:1 245:1 256:1 258:1 280:1 416:1 565:1 568:1 569:1 570:1 571:1
-1 	|BT| (NP (NP (NN Methylation) (NN rate) (NN SPARC) (NN gene)) (NP (NP (CD 80) (NN %)) (NP (CD ten) (JJ gastric) (NN cancer) (NN cell) (NN line)) (NP (NP (CD 74) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 163) (CD 220)) (-RRB- -RRB-))) (NP (JJ primary) (NN tumor))) (, ,) (NP (NP (ADJP (CD 5) (NN %)) (JJ normal) (JJ gastric) (NN mucosa)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 40)))) (-RRB- -RRB-)))) |ET| |BS|8:C04 36:G02.111.087.029.538 37:D12.776.157.125.715 94:A11.251.210 171:E05.318.308.985.775.500 172:A03.556.875.875.440 173:C07.465.864.500|ES| 2:1 7:1 9:1 10:1 14:1 18:1 19:1 41:1 82:1 86:1 94:1 118:1 264:1 344:1 369:1 572:1 573:1 574:1 575:1 576:1 577:1 578:1 579:1 580:1 581:1 582:1
-1 	|BT| (FRAG (NP (S (NP (NP (NNS Mice) (NN mutation) (NN mismatch) (NN repair) (NN gene)) (, ,) (NP (NN Msh2) (NN Mlh1)) (, ,)) (VP (VBP exhibit) (S (NP (NN mismatch) (NN repair) (NN defect)) (VP (VBN predisposed) (S (VP (VBG developing) (NP (JJ gastrointestinal) (NN cancer)))))))) (, ,) (NN lymphoma) (NN tumor) (NN organ) (NN system))) |ET| |BS|6:G05.360.340.024.340 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 174:G02.111.087.219.220 175:J01.897.280.500.269 176:C04.557.386|ES| 2:1 7:1 9:1 18:1 19:1 34:1 183:1 513:1 583:1 584:1 585:1 586:1 587:1 588:1 589:1 590:1 591:1 592:1 593:1
-1 	|BT| (S (S (NP (NN miR-137) (NN overexpression)) (VP (VBD resulted) (NP (NP (NN downregulation) (NN CAR) (NN protein) (NN mRNA)) (PRN (-LRB- -LRB-) (PP (IN via) (NP (NN mRNA) (NN degradation))) (-RRB- -RRB-))))) (: ;) (S (VBN sensitized) (NP (JJ doxorubicin-resistant) (NN cell) (NN doxorubicin)) (-LRB- -LRB-) (VP (VP (VBN shown) (S (VP (VBN reduced) (NP (NN proliferation))))) (, ,) (VP (VBD increased) (NP (NN apoptosis))) (VP (VBD increased) (NP (JJ G2-phase) (NN cell) (NN cycle) (NN arrest))) (SINV (-RRB- -RRB-) (NP (VBD reduced) (FW vivo) (NN growth) (NN rate) (NN neuroblastoma) (NN xenograft)))))) |ET| |BS|7:D12.776 39:G04.299.139.160 41:A11 45:G07.700.320.249 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 111:D13.444.735.544 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 177:G04.299.134.109.500 178:G02.111.780|ES| 2:1 4:1 10:1 14:1 19:1 41:1 47:1 89:1 94:1 102:1 152:1 217:1 237:1 265:1 299:1 325:1 378:1 420:1 421:1 423:1 424:1 452:1 594:1 595:1 596:1 597:1 598:1 599:1 600:1 601:1 602:1
-1 	|BT| (S (NP (NN miR-137)) (VP (VBZ regulates) (SBAR (S (NP (JJ constitutive) (NN androstane) (NN receptor)) (VP (VBZ modulates) (NP (NN doxorubicin) (NN sensitivity) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320|ES| 19:1 94:1 186:1 420:1 422:1 423:1 424:1 599:1 603:1 604:1 605:1 606:1 607:1
-1 	|BT| (S (NP (NN miR-490-3p)) (VP (VBD exhibited) (NP (NP (JJ progressive) (NN downregulation) (NN gastritis)) (, ,) (NP (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN adenocarcinoma) (NN H))))) |ET| |BS|47:A03.556.124 48:C23.550.589 84:C04.557.470.200.025 85:G02.111.087.225 175:J01.897.280.500.269 179:D01.248.497.300.459.700 180:C06.405.205.697|ES| 2:1 19:1 109:1 110:1 255:1 595:1 608:1 609:1 610:1 611:1 612:1
-1 	|BT| (S (NP (NN Mir-660)) (VP (VBD downregulated) (SBAR (S (NP (NN lung) (NN cancer) (NN patient) (NN replacement)) (VP (VBZ inhibits) (NP (NP (NN lung) (NN tumorigenesis)) (VP (VBG targeting) (NP (NN MDM2-p53) (NN interaction))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 32:C04.697.098.500 33:C04.697.098 50:M01.643 122:C14.280.383 181:E04.936.494 182:A04.411|ES| 18:1 19:1 78:1 120:1 328:1 426:1 613:1 614:1 615:1 616:1 617:1 618:1
-1 	|BT| (S (NP (NP (NN miRNA-141)) (, ,) (VP (VBD downregulated) (NP (JJ pancreatic) (NN cancer))) (, ,)) (VP (VBZ inhibits) (NP (NN cell) (NN proliferation) (NN invasion)) (S (VP (ADVP (RB directly)) (VBG targeting) (NP (NN MAP4K4)))))) |ET| |BS|122:C14.280.383 183:G04.299.233.750 184:D13.150.650.319|ES| 2:1 18:1 19:1 94:1 299:1 426:1 465:1 467:1 615:1 616:1 619:1 620:1 621:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (VP (VBD identified) (SBAR (S (NP (NN Usp28) (NN c-MYC) (NN target) (NN gene)) (ADVP (RB highly)) (VBD expressed) (NP (JJ murine) (JJ human) (JJ intestinal) (NN cancer)) (, ,) (VP (VBZ indicates) (SBAR (S (NP (NN USP28) (NN c-MYC) (NN form) (JJ positive) (NN feedback) (NN loop)) (VP (VBZ maintains) (NP (JJ high) (NN c-MYC) (NN protein) (NN level) (NN tumor)))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 83:L01.143.283.425 101:C04.588.274.476.411 185:G05.360.340.024.340.375.500.791.420 186:G05.360.340.024.340.375.500.791.420 187:D08.622.705 188:N02.628 189:V02.460|ES| 2:1 4:1 6:1 7:1 9:1 18:1 19:1 36:1 109:1 160:1 178:1 233:1 247:1 248:1 249:1 622:1 623:1 624:1 625:1 626:1 627:1 628:1 629:1 630:1 631:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (JJ gastric) (NN cancer) (JJ human)) (ADVP (RB often)) (VP (VBD preceded) (NP (NP (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN phenotype))) (S (VP (VBD described) (SBAR (S (ADVP (RB strongly)) (VP (VBZ suggests) (NP (NP (NN involvement) (NN Cdx2) (NN initiation) (NN process)) (VBG leading) (JJ intestinal) (NN neoplasia) (JJ gastric) (NN mucosa))))))))) |ET| |BS|47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 86:D01.268.556.435 190:C04.588.274.476.767 191:A03.556.124.369|ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 213:1 236:1 331:1 579:1 622:1 632:1 633:1 634:1 635:1 636:1 637:1 638:1 639:1 640:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN CDX2) (NN expression)) (ADVP (RB progressively)) (VP (VBD reduced) (NP (JJ gastric) (NN dysplasia) (NN cancer)))) |ET| |BS|70:A03.556.875.875|ES| 2:1 18:1 19:1 86:1 114:1 115:1 201:1 203:1 452:1 622:1
-1 	|BT| (S (NP (NP (NN Mutation) (NN Pla2g2a)) (, ,) (NP (JJ secretory) (NN phospholipase) (NN A) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (NP (NN gene)) (, ,)) (VP (VP (ADVP (RB dramatically)) (VB increase) (NP (NN number) (JJ intestinal) (NN polyp)) (VP (VB develop) (NP (NP (NP (JJ multiple) (JJ intestinal) (NN neoplasia)) (PRN (-LRB- -LRB-) (NP (NN Min)) (-RRB- -RRB-))) (NN mouse)))) (, ,) (NP (JJ murine) (ADJP (NN model) (JJ adenomatous) (NN polyposis) (NN coli) (JJ human))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 102:C04.588.274.476.411 192:D08.811.277.352.100.680.750.937.750 193:C23.300.825.411|ES| 2:1 9:1 10:1 14:1 19:1 36:1 40:1 52:1 57:1 58:1 59:1 69:1 72:1 109:1 148:1 627:1 640:1 641:1 642:1 643:1 644:1 645:1 646:1 647:1 648:1 649:1 650:1
-1 	|BT| (S (NP (NN Notch1)) (ADVP (RB directly)) (VP (VBD induced) (NP (NN CD133) (NN expression) (JJ human) (JJ diffuse) (NN type) (JJ gastric) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 36:1 86:1 115:1 412:1 543:1 621:1 651:1 652:1 653:1
-1 	|BT| (S (NP (NP (CD One) (JJ common) (JJ rate-limiting) (NN mutation)) (JJ human) (NN CRC)) (VP (VBZ occurs) (NP (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene)))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 194:G05.355.044.250.750|ES| 9:1 10:1 11:1 14:1 19:1 34:1 36:1 57:1 58:1 59:1 245:1 654:1 655:1 656:1 657:1
-1 	|BT| (S (NP (PRP$ Our) (NP (NP (JJ recent) (JJ global) (NN analysis) (NN CpG) (NN island) (NN hypermethylation) (NN gene) (NN expression) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NN cell) (NN line)) (VP (VBD revealed) (S (NP (NN SOX17) (NN gene) (NN silencing)) (NP (VBN associated) (NN DNA) (NN hypermethylation) (NN CpG) (NN island) (NN promoter) (NN region))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 42:G05.355.315.203.374 94:A11.251.210 155:G05.355.310 195:G02.111.570.080.380.160 196:G02.111.570.080.689.675 197:A01.456.505.420 198:D13.444.308|ES| 9:1 10:1 14:1 17:1 18:1 19:1 83:1 94:1 100:1 115:1 169:1 245:1 264:1 275:1 658:1 659:1 660:1 661:1 662:1 663:1 664:1 665:1 666:1 667:1
-1 	|BT| (NP (NP (NP (NN Overexpression) (NN miR-141) (JJ pancreatic) (NN cancer) (NN cell)) (VBD inhibited) (NP (NN cell) (NN proliferation)) (, ,) (NP (NP (NN clonogenicity)) (, ,) (NP (NN invasion)) (: ;) (NP (VBN induced) (NN G1) (NN arrest) (NN apoptosis)) (: ;) (NP (VBN enhanced) (NN chemosensitivity))))) |ET| |BS|39:G04.299.139.160 41:A11 122:C14.280.383 183:G04.299.233.750|ES| 2:1 18:1 19:1 89:1 94:1 217:1 299:1 365:1 385:1 386:1 412:1 463:1 467:1 602:1 620:1 668:1 669:1 670:1
-1 	|BT| (S (NP (NP (NP (NN Overexpression) (NN progastrin)) (, ,) (NP (JJ nonamidated) (ADJP (RB incompletely) (VBN processed)) (NN product) (NN gastrin) (NN gene)) (, ,)) (VP (VBN shown) (VP (VBP induce) (NP (JJ colonic) (NN hyperproliferation))))) (VP (VBP promote) (NP (NP (JJ colorectal) (NN cancer) (NN mouse)) (, ,) (NP (NP (NN mechanism) (NN pathogenesis)) (VP (VBN defined)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 199:D06.472.317.413 200:D06.472.317.413|ES| 2:1 9:1 17:1 18:1 19:1 52:1 162:1 237:1 243:1 501:1 668:1 671:1 672:1 673:1 674:1 675:1 676:1 677:1 678:1 679:1 680:1
-1 	|BT| (S (NP (NN p53) (NN activation) (NN CRC) (NN cell)) (VP (VBD interfered) (NP (JJ IL-6-induced) (NN invasion) (NN migration)) (PP (IN via) (NP (JJ miR-34a-dependent) (NN downregulation) (NN IL6R) (NN expression))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 85:G02.111.087.225 201:D12.644.276.374.465.224|ES| 12:1 19:1 94:1 115:1 225:1 245:1 514:1 595:1 596:1 620:1 681:1 682:1 683:1 684:1
-1 	|BT| (S (NP (NN Penta-1,2,3,4,6-O-galloyl-beta-D-glucose)) (VP (VP (VBZ induces) (SBAR (S (NP (NN p53)) (VP (VBZ inhibits) (NP (NN STAT3) (NN prostate) (NN cancer) (NN cell) (NN vitro)))))) (VP (VBZ suppresses) (NP (NN prostate) (NN xenograft) (NN tumor) (NN growth)) (FW vivo)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 82:D12.644.360.024.342.300 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 202:C04.588.945.440.770|ES| 7:1 12:1 18:1 19:1 77:1 94:1 102:1 214:1 216:1 251:1 265:1 378:1 615:1 685:1 686:1
-1 	|BT| (NP (NP (NN PURPOSE) (CC AND) (JJ EXPERIMENTAL) (NN DESIGN)) (: :) (NP (NP (DT The) (JJ molecular) (NN mechanism) (NN p14ARF) (NN gene)) (ADJP (JJ altered) (SBAR (S (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (VP (NN complex) (ADJP (JJ unclear)))))))) |ET| |BS|110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375 204:E05.581.500 205:E05.581.500|ES| 9:1 10:1 14:1 18:1 19:1 94:1 104:1 161:1 162:1 328:1 329:1 443:1 687:1 688:1 689:1 690:1 691:1 692:1 693:1 694:1 695:1
-1 	|BT| (NP (NP (NP (NN PURPOSE) (: :)) (NN IFITM3) (, ,) (JJ IFN-inducible) (NN gene)) (, ,) (NP (VBN overexpressed) (JJ human) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 9:1 17:1 18:1 19:1 25:1 36:1 104:1 687:1 696:1 697:1
-1 	|BT| (S (NP (NN PURPOSE) (: :)) (NP (DT The) (NN MYC) (NN oncogene)) (ADVP (RB frequently)) (VP (VBN overexpressed) (NP (NN prostate) (NN cancer)))) |ET| |BS||ES| 18:1 19:1 24:1 25:1 77:1 104:1 472:1 687:1 691:1 698:1
-1 	|BT| (NP (NP (NN Regulation) (NN tumor) (NN suppressor) (NN homeogene) (NN Cdx2) (NN HNF4alpha) (JJ intestinal) (NN cancer))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 101:C04.588.274.476.411 142:I01.880.604 206:G05.360.340.024.340.375.249|ES| 7:1 18:1 19:1 109:1 123:1 213:1 699:1 700:1 701:1
-1 	|BT| (FRAG (NP (NNS Results)) (VBP show) (NP (NN KLF9) (JJ haploinsufficient) (NN suppressor) (NN colon) (NN tumorigenesis) (NN Apc)) (-LRB- -LRB-) (NP (NP (NP (NP (NN Min)) (: /) (CC +) (-RRB- -RRB-) (NN mouse) (NN part)) (, ,) (NP (NP (NN repression) (NN ISG15) (NN latter) (POS 's)) (JJ antiapoptotic) (NN function))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 38:Z01.058.290.120.180 40:Z01.542.248.700 46:A03.556.124.526.356 207:G05.365.590.029.530.587 208:F01.393.821|ES| 2:1 10:1 14:1 19:1 33:1 52:1 78:1 113:1 280:1 429:1 451:1 461:1 700:1 702:1 703:1 704:1 705:1 706:1 707:1 708:1 709:1
-1 	|BT| (S (NP (NNS RESULTS) (: :)) (VP (ADVP (RB Herein)) (VB provide) (NP (JJ new) (NP (NN evidence) (JJ transcriptional) (NN regulation)) (NN Notch) (NN PEA3) (NN breast) (NN cancer)))) |ET| |BS|142:I01.880.604 209:G02.111.087.847|ES| 18:1 19:1 23:1 38:1 104:1 256:1 428:1 438:1 559:1 710:1 711:1 712:1 713:1
-1 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (PP (IN In) (NP (NN CRC) (NN cell) (NN line))) (, ,) (VP (VBP mimic) (NP (NN miR-221) (NN miR-222) (VBD activated) (NN NF-kappaB) (NN STAT3)) (, ,) (NP (VBG increasing) (NN expression) (NN miR-221) (NN miR-222))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 82:D12.644.360.024.342.300 94:A11.251.210 210:D12.776.260.600|ES| 2:1 19:1 94:1 104:1 115:1 140:1 141:1 163:1 244:1 245:1 251:1 264:1 567:1 710:1 714:1 715:1
-1 	|BT| (S (NP (NN Sil) (NN gene) (NN expression) (NN lung) (NN cancer)) (VP (VBD correlated) (NP (NN expression) (JJ several) (NN kinetochore) (NN check-point) (NN gene) (JJ histopathologic) (JJ mitotic) (NN index)))) |ET| |BS|155:G05.355.310 211:A11.284.430.106.279.345.190.160.165.500 212:E01.370.225.500.385.500|ES| 9:1 18:1 19:1 115:1 262:1 328:1 446:1 716:1 717:1 718:1 719:1 720:1 721:1
-1 	|BT| (S (NP (NN Silencing) (NN MLH1)) (VP (ADVP (RB frequently)) (VBN seen) (S (NP (JJ sporadic) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 213:F02.830.816.964|ES| 17:1 18:1 19:1 698:1 722:1 723:1 724:1 725:1
-1 	|BT| (S (ADVP (RB Similarly)) (, ,) (NP (NN treatment) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line) (NN hypomethylating) (NN agent)) (VP (VBZ induces) (NP (NP (JJ differentiation-related) (NN gene)) (, ,) (PP (VBG including) (NP (NN CDX1)))))) |ET| |BS|6:G05.360.340.024.340 52:E02 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 94:A11.251.210|ES| 2:1 9:1 18:1 19:1 36:1 94:1 113:1 214:1 264:1 546:1 561:1 726:1 727:1 728:1 729:1 730:1
-1 	|BT| (S (NP (JJ Sonic) (NN hedgehog) (NN inhibitor)) (VP (VBP prevent) (NP (JJ colitis-associated) (NN cancer)) (FRAG (IN via) (NP (VBN orchestrated) (NN mechanism) (NN IL-6)) (: /) (NP (NP (NN gp130) (NN inhibition)) (, ,) (NP (NN 15-PGDH) (NN induction)) (, ,) (NP (NN Bcl-2) (NN abrogation)) (, ,) (NP (NN tumorsphere) (NN inhibition)))))) |ET| |BS|43:F01.145.544 53:C06.405.205.265 54:G05.360.340.024.340.375.500.791.150 201:D12.644.276.374.465.224 214:B01.050.150.900.649.473.376|ES| 2:1 18:1 19:1 103:1 133:1 158:1 162:1 380:1 410:1 596:1 731:1 732:1 733:1 734:1 735:1 736:1 737:1 738:1
-1 	|BT| (S (NP (NN SPDEF)) (VP (VP (VBD inhibited) (NP (NN expression) (JJ beta-catenin-target) (NN gene) (NN mouse) (NN colon) (NN tumor))) (, ,) (VP (VBD interacted) (NP (NP (NN beta-catenin) (NN block) (JJ transcriptional) (NN activity)) (NP (NN CRC) (NN cell) (NN line))) (, ,) (S (VP (VBG resulting) (NP (JJR lower) (NN level) (NN cyclin) (NN D1) (NN c-MYC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 94:A11.251.210 122:C14.280.383 155:G05.355.310 209:G02.111.087.847 215:D12.644.360.262.150.100|ES| 2:1 7:1 9:1 19:1 52:1 60:1 94:1 113:1 115:1 117:1 245:1 249:1 264:1 365:1 384:1 399:1 559:1 625:1 739:1 740:1 741:1 742:1 743:1 744:1
-1 	|BT| (S (NP (JJ Stable) (NN transfection) (NN Ha-ras) (JJ human) (NN colon) (NN cancer) (NN line) (NN CaCo2)) (VP (VBP result) (NP (JJ morphologic) (NN differentiation) (JJ small) (NN bowel) (NN phenotype)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 80:G05.695 216:Z01.107.084.900.425 217:E05.393.350.810 218:A03.556.124.684|ES| 18:1 19:1 36:1 101:1 113:1 215:1 236:1 264:1 745:1 746:1 747:1 748:1 749:1 750:1 751:1
-1 	|BT| (NP (NP (NP (DT The) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene) (NN product)) (NP (VBN mutated) (JJ vast) (NN majority) (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 219:G05.360.340.024.340.375.249.320 220:D05.500.117.249|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 36:1 57:1 58:1 59:1 198:1 229:1 675:1 691:1 752:1
-1 	|BT| (S (NP (DT The) (NN adhesion) (NN molecule) (NN L1CAM)) (VP (VBZ mediates) (S (NP (NN chemoresistance) (NN migration) (NN tumor) (NN cell) (JJ elevated) (NN CRC) (NN tissue)) (NP (VBN associated) (JJ metastatic) (NN spread) (JJ poor) (NN prognosis) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 98:A10 113:C04.697.650 159:I01.880.735.634 163:E01.789 221:D12.776.395.550.200.250.520.578 222:D12.776.395.550.200|ES| 7:1 19:1 94:1 120:1 169:1 180:1 182:1 245:1 272:1 337:1 514:1 544:1 545:1 691:1 753:1 754:1 755:1 756:1 757:1
-1 	|BT| (S (NP (DT The) (NN analysis) (JJ clinical) (JJ characteristic)) (VP (VBD showed) (SBAR (S (NP (NN miR-141)) (ADVP (RB significantly)) (VP (VBD downregulated) (NP (NN tissue) (NN cell) (NN line) (JJ pancreatic) (NN cancer))))))) |ET| |BS|94:A11.251.210 98:A10|ES| 18:1 19:1 84:1 94:1 124:1 132:1 264:1 272:1 336:1 426:1 463:1 467:1 661:1 691:1
-1 	|BT| (S (NP (DT The) (JJ apoptosis-inducing) (NN effect) (NN gastrin) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ relates) (NP (NP (VBN increased) (NP (NN IEX-1)) (NN expression)) (VP (VBG mediating) (NP (NP (NN NF-kappa) (NN B)) (NN inhibition)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 43:F01.145.544 199:D06.472.317.413 200:D06.472.317.413 210:D12.776.260.600|ES| 17:1 18:1 19:1 47:1 75:1 94:1 103:1 115:1 676:1 691:1 758:1 759:1 760:1 761:1 762:1 763:1
-1 	|BT| (S (NP (DT The) (NN CDX2) (NN expression) (JJ gastric) (NN cancer)) (ADVP (RB also)) (ADVP (RB inversely)) (VP (VBD correlated) (NP (NN expression) (JJ gastric) (NN mucin)))) |ET| |BS|72:D12.776.395.560.631.100|ES| 5:1 18:1 19:1 86:1 114:1 115:1 209:1 418:1 446:1 691:1
-1 	|BT| (NP (NP (DT The) (NN ECM-modulator) (NN inter)) (: -) (S (NP (NP (NN alpha-trypsin) (NN inhibitor) (JJ heavy) (NN chain) (NN family) (NN member)) (CD five) (-LRB- -LRB-) (NN ITIH5) (-RRB- -RRB-)) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (NN tumor) (NN suppressor)) (VP (ADVP (RB potentially)) (VP (VBN involved) (NP (NP (VBG impairing) (NN breast) (NN cancer) (NN progression) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (S (NP (NN function)) (ADJP (ADVP (RB still)) (JJ elusive))))))))))) |ET| |BS|16:C23.550.291.656 44:F01.829.263 206:G05.360.340.024.340.375.249 223:A11.284.295.310|ES| 7:1 10:1 14:1 18:1 19:1 23:1 33:1 48:1 97:1 161:1 162:1 380:1 435:1 623:1 691:1 700:1 764:1 765:1 766:1 767:1 768:1 769:1 770:1 771:1 772:1 773:1 774:1 775:1 776:1 777:1
-1 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
-1 	|BT| (FRAG (NP (NP (DT The) (NN level) (NN miR-221) (NN miR-222)) (RRC (ADVP (RB well)) (NP (NP (NN RelA)) (, ,) (NP (NN STAT3)) (, ,) (NP (NP (NN PDLIM2) (NNS mRNAs)) (VP (VBN measured) (NP (CD 57) (JJ paired) (NN CRC) (JJ adjacent) (JJ nontumor) (NN tissue) (NN patient)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544 228:E05.978|ES| 2:1 19:1 120:1 126:1 140:1 141:1 245:1 249:1 250:1 251:1 272:1 326:1 445:1 447:1 691:1 787:1 788:1 789:1 790:1
-1 	|BT| (NP (NP (DT The) (NN role) (NN KCNQ1) (NN mouse) (JJ human) (JJ gastrointestinal) (NN cancer))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 31:1 36:1 52:1 183:1 691:1 791:1
-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP provide) (NP (NN evidence) (NN Cdx2) (VP (VBZ antagonizes) (NP (NN process) (NN tumor) (NN cell) (NN dissemination))))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN homeobox) (NN gene)) (VP (MD might) (VP (VB represent) (NP (JJ new) (JJ therapeutic) (NN target) (JJ metastatic) (NN spreading) (NN colon) (NN cancer))))))))) |ET| |BS|8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04|ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (S (NP (NN K-sam) (NN overexpression)) (VP (VBN associated) (NP (JJ malignant) (NN phenotype) (JJ undifferentiated) (NN type) (NN stomach) (NN cancer)))) (, ,) (NP (JJ infiltrative) (NN growth) (NN metastasis)))))) |ET| |BS|45:G07.700.320.249 80:G05.695 113:C04.697.650 231:C04.557.465.625.600.380.590 232:D02.886.030.676.180|ES| 2:1 18:1 19:1 101:1 102:1 152:1 169:1 236:1 543:1 792:1 796:1 801:1 802:1 803:1 804:1 805:1 806:1
-1 	|BT| (S (S (NP (DT This) (JJ K-Ras) (NN tumor) (NN phenotype)) (VP (VBN associated) (VP (VBD attenuated) (NP (NN signaling) (NN MAPK) (NN pathway))))) (, ,) (NP (JJ human) (NN colon) (NN cancer) (NN cell)) (VP (VBG expressing) (NP (NP (JJ mutant) (NN K-Ras) (JJ hypersensitive) (NN inhibition) (NN Raf)) (, ,) (NP (NN Mek))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 80:G05.695 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565|ES| 2:1 7:1 13:1 18:1 19:1 36:1 94:1 103:1 113:1 169:1 195:1 236:1 383:1 807:1 808:1 809:1 810:1 811:1 812:1 813:1 814:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBZ provides) (SBAR (S (NP (NP (JJ first) (JJ quantitative) (NN analysis) (JJ discrete) (NN CRKI) (NN CRKII) (NN protein) (NNS isoforms)) (SBAR (S (NP (JJ human) (NN lung) (NN tumor)) (VP (VBZ provides) (NP (NN evidence) (NN C-CRK) (NN proto-oncogene)))))) (VP (MD may) (VP (VB foment) (NP (JJ aggressive) (NN phenotype) (NN lung) (NN cancer)))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 162:F01.145.126.125 235:G05.360.340.024.340.375.500.791 236:D12.644.360.024.318 237:C04.588.894.797.520 238:D12.776.800|ES| 4:1 7:1 18:1 19:1 36:1 38:1 131:1 236:1 328:1 491:1 538:1 563:1 661:1 807:1 815:1 816:1 817:1 818:1 819:1 820:1 821:1 822:1 823:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBP show) (SBAR (S (NP (NN c-Myc) (JJ critical) (JJ Apc-dependent) (JJ intestinal) (NN tumorigenesis) (NN mouse)) (VP (VBZ provides) (NP (JJ potential) (JJ therapeutic) (NN target) (NN treatment) (JJ colorectal) (NN cancer))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02|ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1
-1 	|BT| (S (S (S (VP (TO To) (VP (VB understand) (NP (NN miR-141))))) (VP (VBZ mediates) (NP (NN phenotype) (JJ pancreatic) (NN cancer) (NN cell)))) (S (, ,) (NP (NNS bioinformatics) (NN tool)) (VP (VBN used) (VP (VBP identify) (NP (NN MAP4K4) (JJ potential) (NN target) (NN miR-141)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 80:G05.695 239:F02.463.188.357 240:H01.158.273.180|ES| 2:1 18:1 19:1 94:1 160:1 236:1 463:1 465:1 467:1 476:1 755:1 827:1 828:1 829:1 830:1 831:1 832:1
-1 	|BT| (FRAG (PP (TO To) (NP (VB investigate) (NP (NP (NN role) (NN KCNQ1) (JJ human) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN measured) (NN protein) (NN level) (NN KCNQ1) (NN immunohistochemistry) (NN tissue) (NNS microarrays)) (VP (VBG containing) (NP (NP (NN sample) (NN CRC) (NN patient) (NN liver) (NN metastasis)) (VP (VBN undergone) (NP (JJ hepatic) (NN resection))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 38:Z01.058.290.120.180 40:Z01.542.248.700 50:M01.643 55:B01.050.150.900.649.801.400.112.400.400 98:A10 113:C04.697.650 143:E01.370.225.500.607.512 228:E05.978 241:D12.776.157.530.400.600.900.124.249.500 242:A03.620|ES| 2:1 4:1 10:1 14:1 17:1 18:1 19:1 31:1 36:1 120:1 128:1 245:1 249:1 272:1 286:1 459:1 789:1 791:1 806:1 828:1 833:1 834:1 835:1 836:1 837:1 838:1
-1 	|BT| (NP (NP (NP (JJ Transient) (JJ stable) (NN overexpression) (NN mir-660)) (S (VP (VBG using) (S (NP (NN miRNA)) (VP (VBP mimic) (SBAR (S (NP (VBN reduced) (NP (NN migration)) (, ,) (NP (NN invasion)) (, ,) (NP (NN proliferation) (NN property))) (VP (VBD increased) (NP (NP (NN apoptosis) (NN p53) (JJ wild-type) (NN lung) (NN cancer) (NN cell)) (PRN (-LRB- -LRB-) (NP (NP (NN NCI-H460)) (, ,) (NP (NN LT73)) (, ,) (NP (NN A549))) (-RRB- -RRB-)))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 120:I01.409.418.750.600.480.150 184:D13.150.650.319|ES| 2:1 8:1 10:1 12:1 14:1 18:1 19:1 47:1 89:1 94:1 152:1 299:1 328:1 350:1 360:1 363:1 364:1 373:1 452:1 514:1 567:1 620:1 839:1 840:1 841:1 842:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD aimed) (VP (VB investigate) (SBAR (IN whether) (S (NP (NN Notch1) (NN signaling)) (VP (VBZ contributes) (NP (NN carcinogenesis) (JJ gastric) (NN cancer) (NN CD133) (NN induction)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 69:G02.111.087.800|ES| 18:1 19:1 86:1 195:1 207:1 221:1 459:1 651:1 652:1 736:1 843:1 844:1 845:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (JJ biological) (NN function) (NP (NP (JJ related) (JJ molecular) (NN mechanism) (NN PAX5) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|104:C04.557.470.200.025.255 141:G16.100 243:D12.776.260.645.500|ES| 10:1 14:1 19:1 33:1 161:1 162:1 303:1 304:1 324:1 419:1 440:1 441:1 843:1 846:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (NN apobec-1) (NN gene) (NN expression) (JJ human) (JJ gastrointestinal) (NN tumor) (NN colon) (JJ cancer-derived) (NN cell) (NN line)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 155:G05.355.310 244:C04.588.274.476|ES| 7:1 9:1 19:1 36:1 94:1 113:1 115:1 183:1 264:1 324:1 843:1 847:1 848:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (NN rat) (NN model)) (VP (VBG carrying) (NP (JJ knockout) (NN allele) (NN gatekeeper) (NN gene) (NNP Adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN Apc) (-RRB- -RRB-)))) (VP (VBZ recapitulates) (NP (NP (JJ familial) (NN colon) (NN cancer)) (JJ human) (S (ADVP (RB closely)) (VP (VBG existing) (NP (JJ murine) (NN model)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 21:G05.360.340.024.340.375.249.050 44:F01.829.263 55:B01.050.150.900.649.801.400.112.400.400 77:G05.360.340.024.340.030 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 247:G01.374.676.530 248:E05.393.335.750|ES| 9:1 10:1 14:1 18:1 19:1 36:1 58:1 59:1 71:1 72:1 113:1 221:1 230:1 280:1 403:1 627:1 843:1 849:1 850:1 851:1 852:1 853:1 854:1 855:1 856:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NN microRNA) (NN miR-221) (NN miR-222)) (VP (VBP regulate) (NP (NP (NP (NN NF-kappaB) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (NN activation) (JJ human) (NN CRC) (NN cell) (NN line)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 184:D13.150.650.319 210:D12.776.260.600 249:G05.355.315.800 250:E07.305.812|ES| 10:1 14:1 19:1 36:1 94:1 140:1 141:1 221:1 225:1 245:1 251:1 264:1 403:1 487:1 714:1 843:1 857:1 858:1 859:1 860:1 861:1 862:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD wanted) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (JJ genetic) (NN defect) (JJ relevant) (JJ colorectal) (NN cancer)) (, ,) (NP (NN Msh2) (NN p53) (NN deficiency)) (, ,)) (VP (MD would) (VP (VB influence) (NP (NN efficiency) (NN sulindac) (NN chemoprevention) (NN increase) (NN side) (NN effect))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 87:C18.654.521 251:D02.455.426.559.847.486.875 252:F02.784.692.351 253:E02.319.162 254:C16.131|ES| 2:1 12:1 17:1 18:1 19:1 40:1 74:1 75:1 221:1 253:1 585:1 588:1 843:1 863:1 864:1 865:1 866:1 867:1 868:1 869:1 870:1 871:1
-1 	|BT| (S (NP (NP (NP (NN Western) (NN blot) (JJ quantitative) (JJ real-time) (NN PCR)) (PRN (-LRB- -LRB-) (NP (NN qRT-PCR)) (-RRB- -RRB-))) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NN MAP4K4) (NN expression)) (VP (ADVP (RB inversely)) (VBD correlated) (NP (NN miR-141) (NN expression) (JJ pancreatic) (NN cancer) (NN sample) (NN cell) (NN line))))))) |ET| |BS|94:A11.251.210 255:E05.196.401.143 256:E05.196.401.143 257:E05.393.620.500.706|ES| 10:1 14:1 18:1 19:1 94:1 115:1 264:1 275:1 418:1 446:1 463:1 465:1 467:1 661:1 817:1 835:1 872:1 873:1 874:1 875:1 876:1
-1 	|BT| (S (NP (NN Western) (NN blot)) (VP (VBD revealed) (NP (NP (NN overexpression) (NN beta-catenin)) (, ,) (NP (NP (NN c-Myc)) (, ,) (NP (NN cyclin) (NN D1)) (, ,) (NP (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (NP (NN cyclooxygenase-2) (NN colon) (NN tumor) (NN sample)))))) |ET| |BS|22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 51:C04.588.274.476.411.307.180 215:D12.644.360.262.150.100 255:E05.196.401.143|ES| 2:1 7:1 19:1 60:1 61:1 63:1 64:1 65:1 66:1 113:1 152:1 275:1 743:1 744:1 824:1 835:1 872:1 873:1
-1 	|BT| (S (NP (NN Wnt/beta-catenin) (NN signaling) (JJ critical) (JJ intestinal) (NN cell) (NN proliferation)) (, ,) (VP (VBD decreased) (NP (NN CDX2) (NN expression) (NN influence) (NN Wnt) (JJ signaling-related) (NN gene) (NN progression) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 16:C23.550.291.656 47:A03.556.124 69:G02.111.087.800 105:G02.149.115.800.925 183:G04.299.233.750|ES| 2:1 9:1 17:1 18:1 19:1 48:1 94:1 109:1 114:1 115:1 195:1 202:1 299:1 302:1 825:1 867:1 877:1 878:1
-1 	|BT| (S (NP (NN YY1)) (VP (VBZ promotes) (NP (NP (NN colon) (NN cancer) (NN growth)) (VP (VBG inhibiting) (NP (NP (NN p53)) (S (VP (VBG promoting) (NP (NN Wnt) (NN signaling) (NN pathway) (NN serf) (JJ independent) (JJ prognostic) (NN biomarker) (NN CRC) (NN patient))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 45:G07.700.320.249 50:M01.643 122:C14.280.383 147:G02.149.115.800.925 158:D23.101 258:D12.776.260.235.875|ES| 12:1 18:1 19:1 102:1 113:1 120:1 195:1 245:1 298:1 383:1 877:1 879:1 880:1 881:1 882:1 883:1 884:1 885:1
-1 	|BT| (S (NP (JJ Genetic) (NN analysis) (NN C/EBPalpha) (NN gene) (NN progress)) (VP (ADVP (RB fully)) (VB evaluate) (NP (ADJP (NN role) (JJ novel)) (NN tumor) (NN suppressor) (NN lung) (NN cancer)))) |ET| |BS|15:F01.829.316.616 206:G05.360.340.024.340.375.249 225:E05.337 259:D12.776.395.240.150.500 260:E01.370.225.562|ES| 7:1 9:1 18:1 19:1 31:1 328:1 661:1 700:1 886:1 887:1 888:1 889:1 890:1 891:1
-1 	|BT| (S (NP (JJ Preneoplastic) (JJ neoplastic) (NNS hepatocytes)) (VP (VBP undergo) (NP (NN c-Myc) (NN up-regulation) (NN overgrowth) (NN rat)) (NP (NP (RB genetically) (JJ susceptible) (NN hepatocarcinogenesis)) (, ,) (NP (JJ resistant) (NN rat))))) |ET| |BS|8:C04 142:I01.880.604 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 261:C23.550.291.687.500 262:A11.436.348|ES| 2:1 19:1 427:1 824:1 849:1 892:1 893:1 894:1 895:1 896:1 897:1 898:1 899:1 900:1
-1 	|BT| (NP (NP (NP (DT The) (NN HER2/neu) (NN oncogene) (JJ important) (JJ diagnostic) (JJ prognostic) (NN factor)) (NP (JJ therapeutic) (NN target) (NN breast) (NN cancer)))) |ET| |BS|9:G05.360.340.024.340.375.500 10:A01.236 52:E02 63:G05.360.340.024.340.375.500.791.295.305 263:E01|ES| 18:1 19:1 23:1 24:1 160:1 185:1 541:1 691:1 884:1 901:1 902:1 903:1
-1 	|BT| (S (NP (DT A) (JJR better) (NN understanding) (NN mechanism) (NN Cby) (NN gene) (NN activation) (NN LSCC)) (VP (MD could) (VP (VB provide) (NP (JJ potential) (JJ novel) (JJ therapeutic) (NN target) (JJ human) (JJ laryngeal) (NN carcinoma))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 239:F02.463.188.357 259:D12.776.395.240.150.500 264:G05.355.315.800 265:C04.557.470.200 266:E07.695.450 267:A04.329|ES| 9:1 19:1 36:1 69:1 160:1 162:1 225:1 304:1 541:1 711:1 827:1 891:1 904:1 905:1 906:1 907:1 908:1 909:1
-1 	|BT| (S (NP (NP (DT A) (JJ functional) (JJ genomic) (NN approach)) (VP (VBG integrating) (NP (NP (NN microarray) (JJ proteomic) (NN analysis)) (VP (VBN done) (NP (NN laboratory)))))) (VP (VBD identified) (NP (JJ 14-3-3zeta) (JJ putative) (NN oncogene)) (WHNP (WHNP (WP$ whose) (NN activation)) (NP (JJ common) (VBN driven) (JJ genomic) (NN amplification) (NN lung) (NN adenocarcinoma))))) |ET| |BS|9:G05.360.340.024.340.375.500 66:F01.658.293 268:H01.158.273.180.350 269:G05.360.340 270:H01.158.201.843 271:N02.278.487|ES| 19:1 24:1 69:1 225:1 255:1 328:1 415:1 623:1 655:1 661:1 910:1 911:1 912:1 913:1 914:1 915:1 916:1 917:1 918:1 919:1 920:1 921:1
-1 	|BT| (S (NP (DT A) (NN relationship) (JJ renal) (NN tumor) (NN ASPS)) (ADVP (RB initially)) (VP (VBD suggested) (NP (JJ cytogenetic) (NN finding) (JJ balanced) (-LRB- -LRB-) (NN X) (: ;) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN p11) (NN .2) (: ;)) (NP (CD q25)) (-RRB- -RRB-) (SBAR (S (NP (NP (CD two) (NN case)) (, ,) (NP (NN ASPL-TFE3) (NN fusion) (NN transcript))) (VP (VBD confirmed) (NP (JJ reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction))))))) |ET| |BS|272:E05.393.620.500.725 273:H01.158.273.343.180 274:C04.588.945.947.535 275:C23.888|ES| 2:1 7:1 10:1 14:1 19:1 69:1 217:1 223:1 768:1 922:1 923:1 924:1 925:1 926:1 927:1 928:1 929:1 930:1 931:1 932:1 933:1 934:1 935:1 936:1 937:1 938:1 939:1 940:1 941:1
-1 	|BT| (NP (NNS Aberrations) (NP (NP (NP (JJ fragile) (NN histidine) (NN triad)) (PRN (-LRB- -LRB-) (NP (NN FHIT)) (-RRB- -RRB-))) (NN gene) (JJ idiopathic) (JJ pulmonary) (NN fibrosis))) |ET| |BS|6:G05.360.340.024.340 276:C08.381.483.487.500 277:D12.125.072.329|ES| 9:1 10:1 14:1 19:1 942:1 943:1 944:1 945:1 946:1 947:1 948:1 949:1
-1 	|BT| (S (NP (VBG Activating) (NP (NN alteration) (NN variety) (JJ potential) (JJ oncogenic) (NN driver) (NN gene))) (ADVP (RB also)) (VP (VBD identified) (NP (NP (NNP NSCLC)) (, ,) (PP (VBG including) (NP (NN ROS1))) (, ,) (NP (NNP RET)) (, ,) (NP (NN MET)) (, ,) (NP (NN HER2)) (, ,) (NP (NN BRAF))))) |ET| |BS|18:G05.365.590 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 110:C04.588.894.797.520.109.220.249 278:D08.811.913.696.620.682.700.559.842.374 279:D27.888.569.100|ES| 2:1 5:1 9:1 19:1 188:1 329:1 561:1 623:1 827:1 950:1 951:1 952:1 953:1 954:1 955:1 956:1 957:1 958:1
-1 	|BT| (NP (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB examine) (NP (NN status) (NP (NP (JJ clinical) (NN significance) (JJ anaplastic) (NN lymphoma) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN ALK)) (-RRB- -RRB-))) (NN gene) (NP (NP (NN alteration) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN patient)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 104:C04.557.470.200.025.255|ES| 9:1 10:1 14:1 19:1 84:1 104:1 120:1 303:1 304:1 416:1 441:1 470:1 557:1 591:1 828:1 951:1 959:1 960:1 961:1 962:1
-1 	|BT| (NP (NP (NN ALK) (NN gene) (NN copy) (NN number)) (NP (NN gain) (JJ clinical) (NN significance) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 280:G05.380.350|ES| 9:1 19:1 84:1 303:1 304:1 557:1 646:1 962:1 963:1 964:1
-1 	|BT| (S (NP (DT All) (NN fusion)) (VP (VBD identified) (SBAR (S (NP (NP (NNP RET) (NN KIF5B) (NN gene)) (, ,) (NP (NP (NNP RET) (NN fusion) (NN CCDC6) (NN NCOA4) (NN gene)) (, ,) (NP (JJ characteristic) (NN thyroid) (NN cancer)) (, ,))) (VP (VBD identified) (NP (JJ irradiated) (NN lung) (NN cell))))))) |ET| |BS|6:G05.360.340.024.340 13:D01.339.387 41:A11 182:A04.411 281:E02.815|ES| 2:1 9:1 18:1 19:1 94:1 328:1 336:1 623:1 936:1 956:1 965:1 966:1 967:1 968:1 969:1 970:1
-1 	|BT| (NP (NP (NP (NP (JJ Altered) (NN expression) (JJ human) (NN enhancer) (NN filamentation) (CD 1)) (PRN (-LRB- -LRB-) (NP (NP (NN HEF1)) (: ;) (NP (ADJP (RB also) (VBN known)) (NN NEDD9) (NN Cas-L))) (-RRB- -RRB-))) (NP (VBN implicated) (NN progression) (NN melanoma) (, ,) (NN breast) (, ,) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 10:A01.236 16:C23.550.291.656 55:B01.050.150.900.649.801.400.112.400.400 282:C04.557.465.625.650.510|ES| 2:1 5:1 10:1 14:1 19:1 23:1 36:1 48:1 98:1 115:1 217:1 245:1 556:1 971:1 972:1 973:1 974:1 975:1 976:1 977:1 978:1
-1 	|BT| (NP (NP (NP (NP (JJ Altered) (NN expression) (JJ human) (NN enhancer) (NN filamentation) (CD 1)) (PRN (-LRB- -LRB-) (NP (NP (NN HEF1)) (: ;) (NP (ADJP (RB also) (VBN known)) (NN NEDD9) (NN Cas-L))) (-RRB- -RRB-))) (NP (VBN implicated) (NN progression) (NN melanoma) (, ,) (NN breast) (, ,) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 10:A01.236 15:F01.829.316.616 16:C23.550.291.656 32:C04.697.098.500 33:C04.697.098 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 239:F02.463.188.357 282:C04.557.465.625.650.510|ES| 2:1 5:1 10:1 14:1 19:1 23:1 31:1 36:1 48:1 78:1 98:1 115:1 217:1 245:1 433:1 438:1 556:1 889:1 971:1 972:1 973:1 974:1 975:1 976:1 977:1 978:1 979:1
-1 	|BT| (FRAG (SBAR (IN Although) (S (NP (NP (NP (JJ additional) (NN study) (NN animal) (NN model)) (VP (VBN needed) (, ,))) (VP (VBG finding) (VP (VBP suggest) (S (VP (VBG targeting) (NP (NN HMGA2))))))) (VP (MD could) (SBAR (S (NP (RB therapeutically) (JJ beneficial) (NN lung) (NN cancer) (NN cancer)) (VP (VBD characterized) (NP (VBN increased) (NN HMGA2) (NN expression))))))))) |ET| |BS|283:D12.776.260.312.937 284:N03.349.380.420 285:E05.598|ES| 2:1 18:1 19:1 46:1 47:1 72:1 107:1 115:1 131:1 328:1 616:1 796:1 908:1 927:1 980:1 981:1 982:1 983:1 984:1 985:1
-1 	|BT| (FRAG (SBAR (IN Although) (S (NP (NN CTCF)) (VP (VBD described) (NP (NP (NP (ADJP (RB significantly) (VBN mutated)) (NN gene) (JJ endometrial) (NN cancer) (NN TCGA)) (, ,) (NP (NN A) (-LRB- -LRB-) (CD 7) (-RRB- -RRB-) (NN track))) (SBAR (S (NP (JJ variant) (VBG leading) (NN T204) (NNS frameshifts)) (VP (VBD reported))))))))) |ET| |BS|6:G05.360.340.024.340 86:D01.268.556.435 286:C04.588.945.418.948.585 287:G05.365.590.265|ES| 2:1 9:1 10:1 14:1 18:1 19:1 69:1 107:1 124:1 229:1 276:1 634:1 639:1 986:1 987:1 988:1 989:1 990:1 991:1 992:1 993:1
-1 	|BT| (S (SBAR (IN Although) (S (NP (NP (NN therapy)) (VP (VBG targeting) (NP (JJ high) (NN EphA1) (NN expression)))) (VP (VBP seem) (NP (JJ plausible) (NN CRC))))) (, ,) (S (NP (NN loss) (NN expression)) (VP (VBD advanced) (NP (NN disease)))) (VP (VBZ suggests) (SBAR (S (NP (NP (NP (JJ potential) (NN risk)) (VBN targeted) (NN therapy)) (, ,) (VP (VBG selecting) (NP (NN loss) (NN expression))) (, ,)) (VP (MD might) (VP (VB contribute) (NP (NN disease) (NN progression)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 16:C23.550.291.656 38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 61:E05.318.740.600.800 288:C23.550.288|ES| 2:1 16:1 19:1 32:1 48:1 107:1 115:1 130:1 171:1 178:1 245:1 331:1 450:1 616:1 798:1 827:1 994:1 995:1 996:1 997:1 998:1 999:1
-1 	|BT| (S (PP (IN Among) (NP (ADJP (RB frequently) (VBN deleted)) (JJ chromosomal) (NN site))) (, ,) (NP (NN LOH) (NN chromosome) (NN 3p)) (VP (VBD detected) (NP (NN MM)) (, ,) (S (VP (VBG suggesting) (S (NP (NN presence)) (NP (CD one) (NP (JJ several) (NN tumour) (NN suppressor) (NN gene) (JJ important) (NN role)) (NN development) (NN disease))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 206:G05.360.340.024.340.375.249 289:A11.284.187 290:G05.365.590.029.530 291:F03.625.421|ES| 2:1 9:1 19:1 31:1 35:1 262:1 346:1 698:1 700:1 902:1 998:1 1000:1 1001:1 1002:1 1003:1 1004:1 1005:1 1006:1 1007:1 1008:1 1009:1 1010:1 1011:1
-1 	|BT| (S (NP (NN Amplification) (NN over-expression) (NN MAP3K3) (NN gene) (JJ human) (NN breast) (NN cancer)) (VP (VBZ promotes) (NP (NN formation) (NN survival) (NN breast) (NN cancer) (NN cell)))) |ET| |BS|20:G03.495 55:B01.050.150.900.649.801.400.112.400.400 108:G04.299.316 155:G05.355.310|ES| 9:1 18:1 19:1 23:1 36:1 43:1 94:1 274:1 298:1 1012:1 1013:1 1014:1
-1 	|BT| (S (NP (DT An) (JJ integrative) (NN bioinformatics) (NN analysis) (NN region)) (VP (VBN nominated) (NP (NN MAP3K3) (NN gene) (JJ potential) (JJ therapeutic) (NN target) (NN breast) (NN cancer)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 10:A01.236 12:Z01.542.049 52:E02 240:H01.158.273.180 292:Z01|ES| 9:1 18:1 19:1 23:1 160:1 541:1 661:1 667:1 827:1 830:1 1014:1 1015:1 1016:1 1017:1
-1 	|BT| (S (NP (NN Analysis) (NN TP53) (NN CTNNB1) (NN gene) (NN mutation)) (NP (NNP HG) (NN component) (NNS MASCs)) (ADVP (RB well)) (NP (NN detection) (NN copy) (NN number) (NN aberration) (NN EGFR) (NN CCND1) (NN gene)) (VP (VBP harbor) (NP (NN abnormality)))) |ET| |BS|6:G05.360.340.024.340 18:G05.365.590 23:D12.776.091.249 254:C16.131 293:D01.268.556.504 294:G05.360.340.024.340.137|ES| 9:1 19:1 34:1 119:1 187:1 646:1 787:1 963:1 1018:1 1019:1 1020:1 1021:1 1022:1 1023:1 1024:1 1025:1 1026:1 1027:1
-1 	|BT| (NP (NP (PP (IN As) (NP (NN result))) (, ,) (NP (NP (NN CDCA1) (JJ novel) (NN cancer-testis) (NN antigen) (JJ overexpressed) (NN LC)) (, ,) (NP (JJ cholangiocellular) (NN cancer)) (, ,) (NP (JJ urinary) (NN bladder) (NN cancer) (JJ renal) (NN cell) (NN cancer)) (, ,) (NP (NN CDCA1)) (VP (MD may) (ADVP (RB therefore)) (NP (JJ ideal) (NN TAA) (JJ useful) (NN diagnosis) (NN immunotherapy) (NN cancer)))))) |ET| |BS|259:D12.776.395.240.150.500 263:E01 295:C04.557.470.200.025.390 296:D02.065.064.786 297:C14.907.055.239.125 298:E02.095.465.425 299:D23.050|ES| 2:1 18:1 19:1 25:1 94:1 101:1 168:1 218:1 491:1 564:1 891:1 922:1 1028:1 1029:1 1030:1 1031:1 1032:1 1033:1 1034:1 1035:1 1036:1 1037:1 1038:1
-1 	|BT| (S (PP (IN As) (NP (NP (NN Bim) (NN expression) (JJ critical) (NN biomarker) (NN response)) (NP (JJ many) (VBN targeted) (NN therapy)))) (, ,) (NP (NN PTK6) (NN inhibition)) (VP (MD may) (VP (VB offer) (NP (NP (JJ therapeutic) (NN approach)) (VP (VBG treating) (NP (NN patient) (NN Her2) (VBN targeted) (JJ therapy-resistant) (NN breast) (NN cancer))))))) |ET| |BS|43:F01.145.544 50:M01.643 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 158:D23.101|ES| 2:1 16:1 18:1 19:1 23:1 103:1 115:1 120:1 130:1 168:1 491:1 494:1 541:1 825:1 885:1 911:1 1039:1 1040:1 1041:1 1042:1 1043:1 1044:1 1045:1
-1 	|BT| (S (NP (NN BACKGROUND) (: :)) (NP (NN MUC4) (VBN cloned) (JJ tracheobronchial) (NN mucosa) (NN cDNA)) (ADVP (RB reportedly)) (ADVP (RB highly)) (VP (VBN expressed) (NP (NP (JJ human) (NN malignancy)) (, ,) (PP (VBG including) (NP (NN lung) (NN carcinoma)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 182:A04.411 265:C04.557.470.200 300:D13.444.308.497.220 301:A11.251.353 302:A10.615.550|ES| 2:1 6:1 19:1 36:1 49:1 104:1 304:1 328:1 561:1 579:1 626:1 1046:1 1047:1 1048:1 1049:1 1050:1 1051:1
-1 	|BT| (NP (NP (NP (JJ Basal) (NN cell) (NN carcinosarcoma) (NN PTCH1) (NN mutation)) (NP (JJ epithelial) (JJ sarcomatoid) (JJ primary) (NN tumor) (NN component) (JJ sarcomatoid) (NN metastasis)))) |ET| |BS|8:C04 18:G05.365.590 41:A11 113:C04.697.650 303:C04.557.450.795 304:C04.557.435.290|ES| 7:1 19:1 34:1 94:1 127:1 344:1 806:1 1021:1 1052:1 1053:1 1054:1 1055:1
-1 	|BT| (S (VP (JJ BCL2-like) (NP (NP (CD 11) (NN intron) (CD 2) (NN deletion) (NN polymorphism)) (VP (VBN associated) (NP (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN risk) (NN prognosis)))))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 61:E05.318.740.600.800 110:C04.588.894.797.520.109.220.249 163:E01.789 305:G05.360.340.024.220.400 306:G05.355.600.800 307:G05.365.795|ES| 18:1 19:1 94:1 148:1 169:1 171:1 328:1 544:1 694:1 1056:1 1057:1 1058:1 1059:1 1060:1
-1 	|BT| (S (NP (NN CD133)) (VP (VBN considered) (S (NP (NP (JJ stem-like) (NN cell) (NN marker) (NN cancer)) (PP (VBG including) (NP (NP (JJ gastric) (NN cancer)) (, ,) (NP (NP (NN Notch1) (NN signaling)) (VP (VBN known) (NP (NN play) (JJ important) (NN role) (NN maintenance) (NN differentiation) (JJ stem-like) (NN cell)))))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 74:G04.299.151 79:I03.450.642.693 158:D23.101 188:N02.628 308:A11.872 309:A18.024.937|ES| 2:1 18:1 19:1 31:1 86:1 94:1 195:1 215:1 238:1 534:1 556:1 561:1 651:1 652:1 902:1 1061:1 1062:1 1063:1
-1 	|BT| (NP (NP (NN Characterization) (JJ tumor-suppressive) (NN function) (NN SOX6) (JJ human) (NN esophageal) (JJ squamous) (NN cell) (NN carcinoma))) |ET| |BS|8:C04 55:B01.050.150.900.649.801.400.112.400.400|ES| 19:1 33:1 36:1 94:1 177:1 304:1 1064:1 1065:1 1066:1 1067:1
-1 	|BT| (S (NP (NN Chemokine) (NN gene) (NN expression) (JJ clonal) (NN analysis) (NN B) (NN cell) (NN tissue)) (VP (VBN involved) (NP (JJ lymphoid) (JJ interstitial) (NN pneumonitis) (JJ HIV-infected) (JJ pediatric) (NN patient)))) |ET| |BS|50:M01.643 98:A10 155:G05.355.310 301:A11.251.353 310:A11.063.438 311:B04.820.650.589.650.350 312:C02.782.815.616.400.500 313:D12.644.276.374.200 314:C02.782.815.616.400 315:H02.403.670|ES| 9:1 19:1 94:1 115:1 120:1 272:1 661:1 763:1 774:1 1068:1 1069:1 1070:1 1071:1 1072:1 1073:1 1074:1
-1 	|BT| (S (NP (JJ Chromosomal) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NP (JJ close) (JJ genetic) (NN relationship) (NN papillary) (JJ urothelial) (JJ choriocarcinomatous) (NN tumor) (NN component)) (, ,) (VP (VBG documenting) (NP (JJ first) (NN time) (NN choriocarcinoma) (JJ renal) (NN pelvis)))) (VP (VBP result) (NP (JJ clonal) (NN evolution) (JJ urothelial) (NN carcinoma) (NN acquisition) (JJ trophoblastic) (NN differentiation))))))) |ET| |BS|8:C04 74:G04.299.151 149:G05.360.340.024.340.364.875.890 289:A11.284.187 316:C04.557.465.955.207 317:C04.557.470.200.430 318:A05.810.453.537 319:A11.382.992 320:G04.299.350 321:A10.272.850 322:G01.910|ES| 2:1 7:1 19:1 101:1 215:1 223:1 275:1 304:1 661:1 816:1 864:1 922:1 1021:1 1069:1 1075:1 1076:1 1077:1 1078:1 1079:1 1080:1 1081:1 1082:1 1083:1 1084:1 1085:1 1086:1
-1 	|BT| (S (VP (VBG Combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam) (NN treat) (JJ hepatocellular) (NN carcinoma) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 130:1 303:1 304:1 1087:1 1088:1 1089:1 1090:1
-1 	|BT| (S (NP (NP (JJ Comparative) (NN analysis) (NN expression) (JJ Pathogenesis-Related) (CD 1) (-LRB- -LRB-) (NN P6) (-RRB- -RRB-) (NN gene)) (, ,) (NP (NN marker))) (VP (VBD induced) (NP (NP (NN resistance) (NN pathogen)) (, ,) (NP (NP (JJ various) (NN tissue) (NN tomato) (NN plant)) (VP (VBN treated) (NP (NN CF) (NN root)))) (NP (VBD suggested) (NN B))))) |ET| |BS|6:G05.360.340.024.340 52:E02 98:A10 158:D23.101 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 325:Z01.058.290.100.140 326:A18.400 327:G06.930 328:B01.650|ES| 2:1 9:1 10:1 14:1 19:1 98:1 115:1 272:1 412:1 534:1 661:1 763:1 925:1 1091:1 1092:1 1093:1 1094:1 1095:1 1096:1 1097:1 1098:1 1099:1 1100:1 1101:1
-1 	|BT| (S (NP (NP (NP (JJ Comparative) (NN analysis) (NN expression) (JJ Pathogenesis-Related) (CD 1) (-LRB- -LRB-) (NN P6) (-RRB- -RRB-) (NN gene)) (, ,) (NP (NN marker))) (VP (VBD induced) (NP (NP (NN resistance) (NN pathogen)) (, ,) (NP (NP (JJ various) (NN tissue) (NN tomato) (NN plant)) (VP (VBN treated) (NP (NN CF) (NN root))))))) (VP (VBD suggested) (SBAR (S (NP (NNP B.) (JJ thuringiensis-induced) (NN defense) (NN system)) (VP (VBD activated) (NP (NP (NN leaf)) (, ,) (NP (NN stem)) (, ,) (NP (JJ main) (NN root) (NN tissue)) (, ,) (NP (JJ lateral) (NN root) (NN tissue)))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 98:A10 158:D23.101 309:A18.024.937 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 325:Z01.058.290.100.140 326:A18.400 327:G06.930 328:B01.650 329:A14.549.167.900.750 330:A18.024.812|ES| 2:1 9:1 10:1 14:1 19:1 98:1 115:1 163:1 272:1 412:1 534:1 593:1 661:1 925:1 1091:1 1092:1 1093:1 1094:1 1095:1 1096:1 1097:1 1098:1 1099:1 1100:1 1101:1 1102:1 1103:1 1104:1 1105:1 1106:1 1107:1 1108:1
-1 	|BT| (S (NP (NP (NNS CONCLUSIONS) (: :)) (S (VP (NN DCAMKL-1) (NP (JJ negative) (NN regulator) (NN let-7a) (NN miRNA) (NN biogenesis) (JJ intestinal) (NN stem) (JJ colorectal) (NN cancer) (NN cell)))) (: ;)) (VP (MD could) (VP (VB represent) (NP (JJ novel) (NN target) (JJ anti-cancer) (NN stem) (JJ cell-based) (NN strategy))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 41:A11 47:A03.556.124 184:D13.150.650.319 259:D12.776.395.240.150.500 309:A18.024.937 331:G16.595 332:A11.872.650 333:D01.045|ES| 17:1 18:1 19:1 94:1 104:1 109:1 160:1 217:1 235:1 239:1 449:1 799:1 840:1 891:1 908:1 1106:1 1109:1 1110:1 1111:1 1112:1 1113:1 1114:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Expression) (NN ra) (NN protein) (NN type) (CD II) (JJ alveolar) (NNS pneumocytes) (NN mutation) (NN codon) (CD 12) (JJ K-ras) (NN gene) (NN lung) (NN tissue)) (VP (MD may) (VP (VB contribute) (NP (NN induction) (NN lung) (NN carcinoma) (NN patient) (NN IPF)))))) |ET| |BS|18:G05.365.590 50:M01.643 98:A10 182:A04.411 265:C04.557.470.200 276:C08.381.483.487.500 334:D08.811.277.040.330.300.400.500 335:D13.444.735.544.355 336:A04.411.715.512 337:C08.381.765|ES| 4:1 9:1 19:1 34:1 104:1 120:1 239:1 272:1 304:1 316:1 328:1 450:1 491:1 543:1 736:1 1115:1 1116:1 1117:1 1118:1 1119:1 1120:1 1121:1 1122:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NP (NN Jab1) (NN expression)) (, ,) (NP (ADVP (RB well)) (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN Kip1)) (-RRB- -RRB-))) (NN upregulation)) (, ,) (NP (JJ evident) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN Jab1)) (VP (MD could) (NP (JJ diagnostic) (NN marker) (NN treatment) (NN target) (JJ precancerous) (NN lesion) (JJ early) (NNS HCCs))))))))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 158:D23.101 249:G05.355.315.800 263:E01 338:D12.644.360.225.600 339:G02.111.087.880 340:C17.800.229.400 341:C04.834|ES| 2:1 10:1 14:1 19:1 104:1 115:1 160:1 239:1 534:1 546:1 787:1 900:1 903:1 908:1 1009:1 1123:1 1124:1 1125:1 1126:1 1127:1 1128:1 1129:1 1130:1 1131:1 1132:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Reduction) (NN ING1b) (NN gene) (NN expression)) (VP (VBN associated) (VP (VBD reduced) (NP (NN p21) (NN bax) (NN gene) (NN expression) (NNS NSCLCs)))))) |ET| |BS|110:C04.588.894.797.520.109.220.249 155:G05.355.310 342:D12.644.360.075.718.400|ES| 9:1 19:1 104:1 115:1 169:1 239:1 452:1 1133:1 1134:1 1135:1 1136:1 1137:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT The) (CD two) (NN library)) (ADVP (RB differentially)) (VP (VBD expressed) (SBAR (S (NP (NN gene)) (VP (MD may) (VP (VB provide) (NP (NN basis) (JJ new) (NN insight) (NN clue) (NN finding) (JJ novel) (NN lung) (JJ cancer-related) (NN gene)))))))) (: ;) (S (NP (JJ several) (NN gene)) (ADVP (RB newly)) (VP (VBD found) (NP (NP (NN lung) (NN cancer) (NN ERGIC3)) (VP (VBG seeming) (NP (JJ novel) (NN lung) (JJ cancer-related) (NN gene))))))) |ET| |BS|9:G05.360.340.024.340.375.500 182:A04.411 259:D12.776.395.240.150.500 275:C23.888 343:G05.360.325 344:M01.438|ES| 6:1 9:1 18:1 19:1 37:1 104:1 217:1 239:1 262:1 328:1 491:1 691:1 711:1 712:1 891:1 927:1 933:1 1138:1 1139:1 1140:1 1141:1 1142:1 1143:1 1144:1 1145:1 1146:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NP (DT This) (NN panel)) (SBAR (S (NP (JJ variant-specific) (, ,) (JJ quantitative) (NN RT-PCR) (NN assay)) (VP (VBZ detects) (NP (NP (JJ common) (NN EML4-ALK) (CC +) (JJ variant) (RB well) (NN ALK) (NN gene) (NN expression) (NN level)) (JJ archival) (JJ formalin-fixed) (JJ paraffin-embedded) (NN NSCLC) (NN specimen))))))) |ET| |BS|106:E05.091 110:C04.588.894.797.520.109.220.249 155:G05.355.310 272:E05.393.620.500.725 345:E01.370.225.500.620.720.610 346:E05.393.620.500.706 347:D02.047.407 348:K01.400.152|ES| 2:1 9:1 19:1 104:1 115:1 239:1 249:1 310:1 329:1 510:1 655:1 787:1 807:1 817:1 962:1 990:1 1147:1 1148:1 1149:1 1150:1 1151:1 1152:1 1153:1 1154:1
-1 	|BT| (S (NP (NNS CONCLUSIONS)) (: :) (NP (PRP We)) (VP (VBD provided) (NP (JJ first) (NN evidence) (NN SOX6) (JJ novel) (JJ tumor-suppressor) (NN gene) (NN ESCC) (NN development) (JJ potential) (JJ prognostic) (NN marker) (NN ESCC)))) |ET| |BS|149:G05.360.340.024.340.364.875.890 158:D23.101 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500|ES| 9:1 19:1 35:1 38:1 104:1 239:1 534:1 816:1 827:1 843:1 884:1 891:1 1065:1 1155:1 1156:1 1157:1
-1 	|BT| (S (NP (NN Cyclooxygenase-2) (NN inhibitor)) (VP (VBP down-regulate) (NP (NN osteopontin) (NN Nr4A2-new) (JJ therapeutic) (NN target) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 52:E02 349:D27.505.519.389.310.500 350:D12.644.276.374.625 351:A17.360|ES| 17:1 18:1 19:1 160:1 380:1 541:1 1158:1 1159:1 1160:1 1161:1
-1 	|BT| (S (NP (NP (NP (NN DDR2)) (PRN (-LRB- -LRB-) (NP (NN L63V)) (-RRB- -RRB-))) (: ;) (NP (NP (NN TP53)) (PRN (-LRB- -LRB-) (NP (NN L/L)) (-RRB- -RRB-))) (NP (NN mouse))) (VP (VBD developed) (NP (NP (ADJP (RB poorly) (VBN differentiated)) (NN lung) (NN adenocarcinoma) (JJ transgenic) (NN animal)) (VP (VBN analyzed) (NP (NN latency) (CD 40) (CD 50) (NN week) (NN median) (NN survival) (CD 67.5) (NN week)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 74:G04.299.151 96:I03.784 352:B01.050.050.136|ES| 10:1 14:1 19:1 46:1 52:1 217:1 255:1 274:1 285:1 328:1 368:1 582:1 783:1 1018:1 1162:1 1163:1 1164:1 1165:1 1166:1 1167:1 1168:1 1169:1 1170:1 1171:1
-1 	|BT| (S (NP (NN DEP) (NN domain)) (VP (VP (VBG containing) (NP (CD 1) (-LRB- -LRB-) (NN DEPDC1) (-RRB- -RRB-))) (SBAR (S (NP (ADJP (RB newly) (VBN identified)) (NP (JJ cancer-related) (NN cell) (NN cycle)) (JJ related) (NN gene)) (VP (VBD demonstrated) (NP (JJ novel) (JJ therapeutic) (NN target) (NN bladder) (NN cancer))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 259:D12.776.395.240.150.500 353:G04.299.134|ES| 9:1 10:1 14:1 18:1 19:1 94:1 98:1 160:1 286:1 419:1 541:1 564:1 601:1 623:1 891:1 1143:1 1144:1 1172:1 1173:1 1174:1 1175:1
-1 	|BT| (S (NP (NN DEPDC1)) (VP (VBD required) (NP (NN cell) (NN cycle) (NN progression) (NN motility) (JJ nasopharyngeal) (NN carcinoma)))) |ET| |BS|16:C23.550.291.656 353:G04.299.134|ES| 19:1 48:1 94:1 304:1 601:1 1174:1 1176:1 1177:1 1178:1
-1 	|BT| (S (NP (NN Detection)) (VP (VBN methylated) (S (NP (NN BCL6B)) (VP (MD may) (VP (VB serve) (NP (JJ independent) (NN biomarker) (NN prognosis) (NN GC))))))) |ET| |BS|36:G02.111.087.029.538 158:D23.101 163:E01.789|ES| 19:1 491:1 532:1 544:1 554:1 883:1 885:1 1179:1 1180:1 1181:1
-1 	|BT| (S (NP (NN Detection)) (VP (VBN methylated) (S (NP (NN PAX5)) (VP (VBD utilized) (NP (JJ independent) (JJ prognostic) (NN factor) (NN GC)))))) |ET| |BS|36:G02.111.087.029.538 243:D12.776.260.645.500|ES| 19:1 185:1 554:1 846:1 883:1 884:1 1179:1 1180:1 1182:1
-1 	|BT| (S (NP (NP (NN Detection)) (VP (VBN methylated) (NP (NN TBX5)))) (VP (MD may) (VP (VB serve) (NP (JJ potential) (NN biomarker) (NN prognosis) (NN malignancy))))) |ET| |BS|36:G02.111.087.029.538 158:D23.101 163:E01.789|ES| 19:1 49:1 491:1 532:1 544:1 827:1 885:1 1179:1 1180:1 1183:1
-1 	|BT| (S (NP (NN Detection) (NN TFPI2) (NN methylation) (NN stool) (NN DNA)) (VP (MD may) (VP (VB act) (NP (JJ useful) (NN adjunct) (JJ noninvasive) (NN strategy) (NN screening) (NNS CRCs) (NN future))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 81:E02.095.465.425.400.330.050.400 198:D13.444.308 354:I01.320 355:A12.459|ES| 19:1 81:1 246:1 491:1 666:1 1036:1 1114:1 1179:1 1184:1 1185:1 1186:1 1187:1 1188:1 1189:1 1190:1
-1 	|BT| (NP (NP (NP (NN DLGAP5) (NN overexpression) (JJ evident) (CD 25) (NN %)) (PRN (-LRB- -LRB-) (NP (QP (CD 22) (CD 88))) (-RRB- -RRB-))) (NP (NP (NNP HCC) (NN specimen)) (PP (IN without) (NP (NN AFP) (NN expression)))) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN DLGAP5)) (VP (MD may) (NP (JJ novel) (NN biomarker) (NN HCC) (NN pathogenesis)))))))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101 259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 115:1 152:1 369:1 441:1 491:1 501:1 885:1 891:1 1009:1 1127:1 1154:1 1191:1 1192:1 1193:1 1194:1 1195:1 1196:1
-1 	|BT| (NP (NP (JJ Dual) (JJ therapeutic) (NN effect) (NN interferon-alpha) (NN gene) (NN therapy) (NN rat) (JJ hepatocellular) (NN carcinoma) (NN model) (NN liver) (NN cirrhosis))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 356:D12.644.276.374.440.890.250 357:C06.552.630|ES| 9:1 19:1 72:1 75:1 130:1 303:1 304:1 541:1 836:1 849:1 1197:1 1198:1 1199:1
-1 	|BT| (NP (NP (NN EGFR) (NN gene) (NN mutation) (NN ALK) (NN gene) (NN fusion) (JJ well-characterized) (JJ molecular) (NN target) (NN NSCLC))) |ET| |BS|18:G05.365.590 110:C04.588.894.797.520.109.220.249 358:G05.360.340.024.340.375.500.791.295.300 359:G05.355.760.385|ES| 9:1 19:1 34:1 160:1 161:1 187:1 329:1 936:1 962:1 1200:1
-1 	|BT| (NP (NP (JJ Epigenetic) (NN dysregulation) (JJ leukaemic) (NN HOX) (NN code) (JJ MLL-rearranged) (NN leukaemia) (NN mouse) (NN model))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 360:N04.452.758.708.200.400.500 361:C04.557.337|ES| 19:1 52:1 72:1 1201:1 1202:1 1203:1 1204:1 1205:1 1206:1 1207:1
-1 	|BT| (S (NP (NN Evaluation) (NN RB) (NN status)) (VP (MD may) (NP (JJ useful) (JJ prognostic) (NN factor) (JJ human) (NN HCC)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 225:E05.337|ES| 19:1 36:1 185:1 416:1 441:1 491:1 884:1 1036:1 1208:1 1209:1
-1 	|BT| (S (NP (NN Expression) (NN DRD2)) (VP (VBZ Is) (SBAR (S (NP (VBN Increased) (JJ Human) (JJ Pancreatic) (JJ Ductal) (NN Adenocarcinoma) (NNS Inhibitors)) (VP (VBP Slow) (NP (NN Tumor) (NN Growth) (NNS Mice))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 362:D12.776.543.750.069.300.400.500 363:C04.557.470.200.025.232.750 364:D27.505.696.377.450|ES| 19:1 316:1 444:1 583:1 1210:1 1211:1 1212:1 1213:1 1214:1 1215:1 1216:1 1217:1 1218:1 1219:1
-1 	|BT| (S (NP (NP (NP (CD Fifty-four)) (PRN (-LRB- -LRB-) (NP (CD 73) (NN %)) (-RRB- -RRB-))) (NP (NP (CD 74) (NN lesion) (NNS metaplasias) (JJ bronchiolar) (NN epithelium)) (VP (VBN obtained) (NP (NP (JJ IPF) (NN patient) (NN lung) (NN carcinoma) (CD 8)) (PRN (-LRB- -LRB-) (NP (CD 17) (NN %)) (-RRB- -RRB-))) (NP (NP (CD 46) (NN sample)) (VP (VBN obtained) (NP (NP (JJ IPF) (NN patient)) (PP (IN without) (NP (NN lung) (NN carcinoma))))))))) (VP (VBD showed) (NP (NP (NNP LOH) (NNP FHIT) (NN gene)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.0001)))) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 48:C23.550.589 50:M01.643 62:A10.272 182:A04.411 265:C04.557.470.200 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500|ES| 9:1 10:1 14:1 19:1 120:1 132:1 173:1 304:1 311:1 312:1 328:1 369:1 575:1 781:1 835:1 930:1 946:1 1004:1 1122:1 1131:1 1195:1 1220:1 1221:1 1222:1 1223:1 1224:1 1225:1 1226:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN CD133) (NN DNA) (NN methylation)) (VP (VBZ seems) (VP (VBP constitute) (SBAR (S (NP (JJ abnormal) (NN promoter) (NN signature)) (VP (VBD found) (NP (NP (JJ normal) (NN brain) (NN colon)) (VP (VBN cultured) (NP (JJ primary) (NN tumor)))))))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 366:G02.111.087.029.538.161 367:A08.186.211|ES| 2:1 7:1 19:1 37:1 81:1 83:1 113:1 118:1 334:1 344:1 652:1 666:1 1227:1 1228:1 1229:1 1230:1 1231:1 1232:1
-1 	|BT| (S (NP (NNP Gene) (NN amplification) (NN 17q) (JJ chromosomal) (NN region)) (VP (VBN observed) (ADVP (RB frequently)) (NP (NN breast) (NN cancer)))) |ET| |BS|292:Z01 368:C23.550.210.182|ES| 18:1 19:1 23:1 261:1 667:1 698:1 921:1 1002:1 1233:1 1234:1
-1 	|BT| (S (NP (JJ Genomic) (NN Sequencing)) (VP (VBZ Identifies) (NP (NN ELF3) (NN Driver) (NNP Ampullary) (NNP Carcinoma)))) |ET| |BS|265:C04.557.470.200 268:H01.158.273.180.350 269:G05.360.340|ES| 19:1 1235:1 1236:1 1237:1 1238:1 1239:1 1240:1 1241:1
-1 	|BT| (S (NP (NN HEF1)) (VP (MD may) (VP (VB represent) (NP (NP (JJ attractive) (NN candidate) (NN drug)) (VP (VBG targeting) (NP (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 369:E02.319.300|ES| 19:1 191:1 245:1 491:1 616:1 799:1 974:1 1242:1 1243:1
-1 	|BT| (S (NP (ADJP (RB Here) (VBN investigated)) (NN prevalence) (NN pattern) (NN mutation)) (NP (NP (CD two) (NN gene)) (, ,) (NP (NN Ha-ras) (NN beta-catenin)) (, ,)) (VP (VBN known) (NP (JJ mutational) (NN target) (NN mouse) (NN hepatocarcinogenesis)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 60:E05.318.308.985.525.750 216:Z01.107.084.900.425|ES| 2:1 9:1 19:1 34:1 52:1 60:1 160:1 179:1 260:1 400:1 403:1 556:1 747:1 900:1 933:1 1244:1
-1 	|BT| (S (ADVP (RB Here)) (, ,) (NP (VBD generated) (NN mouse) (NN model) (NN lung) (NN adenocarcinoma)) (VP (VBN driven) (NP (NP (NN mutation) (NN discoidin) (NN domain) (NN receptor) (CD 2) (-LRB- -LRB-) (NN DDR2) (-RRB- -RRB-) (NN gene)) (JJ combined) (NN loss) (NN TP53)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 66:F01.658.293|ES| 2:1 9:1 10:1 14:1 19:1 32:1 34:1 52:1 72:1 73:1 148:1 164:1 186:1 255:1 328:1 400:1 920:1 1018:1 1162:1 1173:1 1245:1
-1 	|BT| (S (NP (JJR Higher) (NN frequency) (JJ inactive) (NN TP53) (NN mutation)) (ADVP (RB also)) (VP (VBN seen) (S (NP (NP (NP (JJ advanced) (NN stage) (NN tumour)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.0003)))) (-RRB- -RRB-))) (NN tumour) (JJ poor) (JJ prognostic) (NN feature)) (NP (ADJP (NP (JJ vascular)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.006)))) (-RRB- -RRB-))) (NP (NP (JJ lymphatic) (NN invasion)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.002)))) (-RRB- -RRB-))))))) |ET| |BS|8:C04 159:I01.880.735.634 194:G05.355.044.250.750 213:F02.830.816.964 370:A15.382.520.301 371:A07.231|ES| 5:1 10:1 14:1 19:1 34:1 311:1 545:1 581:1 620:1 724:1 884:1 997:1 1011:1 1018:1 1129:1 1246:1 1247:1 1248:1 1249:1 1250:1 1251:1 1252:1 1253:1 1254:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NN mutation) (NN exon) (CD 3) (NN beta-catenin) (NN gene)) (VP (VBD detected) (SBAR (S (NP (CD one) (NN tumour)) (VP (VBD expressed) (NP (JJ nuclear) (NN beta-catenin) (JJ lining) (JJ polygonal) (NN component))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 18:G05.365.590 23:D12.776.091.249 372:G05.360.340.024.340.137.232|ES| 2:1 6:1 9:1 19:1 34:1 60:1 433:1 862:1 1007:1 1010:1 1011:1 1021:1 1255:1 1256:1 1257:1 1258:1
-1 	|BT| (S (NP (NN HOX) (NN gene)) (ADVP (RB frequently)) (VP (VBN dysregulated) (NP (NP (JJ human) (NN leukaemia) (NN gene) (NN rearrangement) (JJ mixed) (NN lineage) (NN leukaemia)) (PRN (-LRB- -LRB-) (NP (NN MLL)) (-RRB- -RRB-))) (NP (NN partner) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400 229:G05.360.340.024.340.230.500 361:C04.557.337 373:G05.355.330|ES| 9:1 10:1 14:1 19:1 36:1 698:1 1204:1 1207:1 1259:1 1260:1 1261:1 1262:1 1263:1 1264:1
-1 	|BT| (NP (NP (NP (NN Identification) (NN trophinin) (NN enhancer) (NN cell) (NN invasion) (JJ prognostic) (NN factor)) (JJ early) (NN stage) (NN lung) (NN cancer))) |ET| |BS|41:A11 374:F01.393.446 375:Z01.639.100|ES| 18:1 19:1 94:1 185:1 328:1 620:1 884:1 972:1 1128:1 1129:1 1265:1 1266:1
-1 	|BT| (S (NP (NN IHH) (NN SMO)) (VP (MD may) (SBAR (S (NP (JJ useful) (NNS biomarkers) (JJ diffuse) (NN cancer)) (VP (MD may) (VP (VB show) (NP (NN growth) (NN inhibition) (NN Hh) (NN antagonist) (NN cyclopamine)))))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 376:D23.101.140|ES| 18:1 19:1 102:1 103:1 429:1 491:1 653:1 1036:1 1267:1 1268:1 1269:1 1270:1 1271:1 1272:1
-1 	|BT| (FRAG (PP (IN In) (NP (JJ CF-treated) (JJ main) (NN root))) (, ,) (NP (NP (JJ CF-treated) (JJ lateral) (NN root)) (, ,) (NP (NP (NN expression) (JJ several) (JJ salicylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNP SA)) (-RRB- -RRB-))) (: -) (S (NP (JJ responsive) (JJ defense-related) (NN gene)) (ADVP (RB specifically)) (VP (VBD induced) (, ,) (SBAR (IN whereas) (S (NP (NP (NP (JJ jasmonic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN JA)) (-RRB- -RRB-))) (: -) (NP (JJ related) (NN gene) (NN expression))) (VP (CC either) (VP (VBD down-regulated) (NP (JJ induced) (NN response) (NN CF)))))))))) |ET| |BS|52:E02 142:I01.880.604 155:G05.355.310 325:Z01.058.290.100.140 326:A18.400 351:A17.360 377:D02.241.223.100.300.595.608|ES| 2:1 9:1 10:1 14:1 19:1 39:1 115:1 244:1 262:1 372:1 412:1 494:1 1100:1 1101:1 1107:1 1108:1 1273:1 1274:1 1275:1 1276:1 1277:1 1278:1 1279:1 1280:1 1281:1 1282:1 1283:1
-1 	|BT| (FRAG (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (VBN defined) (NN subset) (NN bone) (JJ soft) (NN tissue) (NN tumor)) (, ,) (PP (VBG including) (NP (JJ benign) (NN tumor))) (, ,) (S (NP (NN Akt)) (ADVP (RB frequently)) (VP (VBN overexpressed) (S (VP (VBN activated))))) (, ,) (NP (NP (NNP AKT1/2) (NN copy) (NN number)) (VP (VBN increased))))) |ET| |BS|378:D08.811.913.696.620.682.700.755 379:C04.588.839 380:A02.835.232 381:C04|ES| 2:1 7:1 19:1 25:1 47:1 163:1 244:1 272:1 561:1 646:1 680:1 698:1 963:1 1284:1 1285:1 1286:1 1287:1 1288:1 1289:1 1290:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN change) (NN level) (NN cdk4)) (VP (MD may) (NP (JJ useful) (NN biomarker) (NN detection) (NN HCC))))))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101|ES| 2:1 19:1 200:1 244:1 249:1 441:1 491:1 796:1 885:1 1023:1 1036:1 1284:1 1291:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN WT1)) (VP (VBD expressed) (NP (NP (JJ substantial) (NN proportion) (NN HCC)) (VP (VBG contributing) (NP (NN tumor) (NN progression) (NN resistance) (NN chemotherapy)))) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN WT1)) (VP (MD may) (NP (JJ important) (NN target) (NN HCC) (NN treatment))))))))) |ET| |BS|8:C04 12:Z01.542.049 16:C23.550.291.656 52:E02 104:C04.557.470.200.025.255 151:E02.319 382:C04.557.435.595|ES| 2:1 6:1 7:1 19:1 48:1 160:1 244:1 441:1 491:1 495:1 546:1 902:1 1009:1 1094:1 1284:1 1292:1 1293:1 1294:1 1295:1
1 	|BT| (S (NP (NP (DT A) (NP (NP (JJ genetic) (NN basis) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (JJ well-established) (JJ major) (NN signaling) (NN pathway)) (, ,) (NP (NP (NN p53)) (, ,) (NP (NN Wnt-signaling)) (, ,) (NP (NP (NP (VBG transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF-beta)) (-RRB- -RRB-))) (NN Ras) (NN pathway))) (, ,)) (VP (VBD identified) (NP (JJ essential) (NN HCC) (NN development)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 104:C04.557.470.200.025.255 126:G02.111.087.800 149:G05.360.340.024.340.364.875.890 503:D12.644.276.374.687|ES| 2:1 10:1 12:1 14:1 19:1 35:1 69:1 102:1 195:1 303:1 304:1 383:1 441:1 462:1 623:1 864:1 1140:1 1770:1 1771:1 1772:1 1773:1 1774:1 1775:1 1776:1
1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (NP (NN p53) (NNS Mutations)) (JJ common) (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (NN induction) (JJ hepatic) (NN p53) (NN expression))) (VP (VBP cause) (SBAR (S (NP (NN lysis)) (VP (VBD implanted) (NP (NN hepatoblastoma) (NN cell) (JJ chimeric) (NN mouse)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 41:A11 55:B01.050.150.900.649.801.400.112.400.400 73:N05.715.350.200 104:C04.557.470.200.025.255 504:C04.557.435.380 505:B05.200|ES| 2:1 12:1 19:1 36:1 52:1 94:1 104:1 115:1 303:1 304:1 655:1 736:1 838:1 1046:1 1410:1 1777:1 1778:1 1779:1 1780:1 1781:1 1782:1 1783:1
1 	|BT| (S (ADVP (RB Instead)) (, ,) (NP (NNS data)) (VP (VBD revealed) (NP (NP (NP (NN Skp2)) (VBN regulated) (NN Myc) (NN activity)) (, ,) (NP (JJ oncogenic) (JJ potential) (NN generation) (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|104:C04.557.470.200.025.255 142:I01.880.604 279:D27.888.569.100 506:F01.829.263.315 507:D12.776.157.743|ES| 2:1 19:1 275:1 303:1 304:1 399:1 793:1 827:1 953:1 1664:1 1784:1 1785:1 1786:1 1787:1
1 	|BT| (NP (NP (NP (NN Loss) (NN miR-122) (NN cause) (JJ chronic) (NN steatohepatitis)) (NP (JJ spontaneous) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|73:N05.715.350.200 104:C04.557.470.200.025.255 508:C06.552.241|ES| 19:1 283:1 303:1 304:1 1779:1 1788:1 1789:1 1790:1 1791:1
1 	|BT| (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NN MAT1A)))) (VP (VBD reduced) (NP (JJ hepatic) (NN S-adenosylmethionine) (NN content) (NN hyperplasia)) (ADVP (RB spontaneously)) (VP (VB develop) (NP (JJ nonalcoholic) (NN steatohepatitis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 232:D02.886.030.676.180 509:C06.552.241.519 510:C23.550.444|ES| 19:1 376:1 452:1 583:1 648:1 838:1 1506:1 1791:1 1792:1 1793:1 1794:1 1795:1 1796:1
1 	|BT| (S (NP (NP (NP (NN MicroRNA-122)) (PRN (-LRB- -LRB-) (NP (NN miR-122)) (-RRB- -RRB-))) (, ,) (NP (ADJP (RB highly) (JJ abundant)) (JJ liver-specific) (NN miRNA)) (, ,)) (VP (VBP act) (NP (NP (NN tumor) (NN suppressor) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|81:E02.095.465.425.400.330.050.400 104:C04.557.470.200.025.255 184:D13.150.650.319 206:G05.360.340.024.340.375.249 242:A03.620|ES| 2:1 7:1 10:1 14:1 19:1 246:1 303:1 304:1 441:1 626:1 700:1 840:1 1789:1 1797:1 1798:1 1799:1
1 	|BT| (S (NP (NP (NP (NN Peroxisome) (JJ proliferator-activated) (NN receptor-gamma1)) (PRN (-LRB- -LRB-) (NP (NN PPARgamma1)) (-RRB- -RRB-))) (JJ important) (NN transcription) (NN factor)) (VP (VBN involved) (NP (NN atherosclerosis) (NN progression)))) |ET| |BS|16:C23.550.291.656 166:D12.776.930 511:C14.907.137.126.307 512:D12.776.826.239 513:C14.907.137.126|ES| 10:1 14:1 19:1 48:1 185:1 487:1 774:1 902:1 1800:1 1801:1 1802:1 1803:1 1804:1
1 	|BT| (S (NP (NP (ADVP (RB Surprisingly)) (, ,) (VBN given) (VBN proposed) (NN role) (NN loss) (NN function) (NN mutation) (NN p53) (NN gene) (NN development)) (NP (JJ human) (JJ colorectal) (NN cancer)) (, ,)) (VP (VBD found) (NP (NP (NN evidence)) (PP (CC either) (NP (NP (NN increase) (NN rate) (NN adenoma) (NN formation) (NN APC)) (CC +) (: /) (: -) (, ,) (NP (NN p53) (: -)) (: /) (FRAG (: -) (NP (NP (NN animal)) (, ,) (NP (NP (VBD increased) (NN rate) (NN progression) (NN malignancy)) (VP (VBN compared) (NP (NP (NN APC)) (NP (CC +) (: /) (: -) (NN p53) (CC +) (FRAG (: /) (CC +) (NP (NN mouse)))))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 13:D01.339.387 14:F01.525 15:F01.829.316.616 16:C23.550.291.656 17:C04.557.470.035 18:G05.365.590 19:B01.050 20:G03.495|ES| 2:1 9:1 11:1 12:1 17:1 18:1 19:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1
1 	|BT| (S (NP (DT The) (NN Tg737) (NN gene)) (VP (VBD investigated) (NP (JJ gross) (NN alteration) (NN series) (NN rodent/human) (NN liver) (NN tumor) (JJ human) (JJ tumorigenic) (NN cell) (NN line)))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 514:B01.050.150.900.649.865 515:C04.588.274.623|ES| 7:1 9:1 19:1 36:1 94:1 264:1 403:1 691:1 836:1 951:1 1805:1 1806:1 1807:1 1808:1 1809:1
1 	|BT| (S (NP (DT A) (NN Cox) (JJ proportional) (NN hazard) (NN model)) (VP (VBD showed) (NP (NP (NN IFITM3) (NN expression) (JJ independent) (JJ prognostic) (NN factor)) (NP (JJ disease-free) (NN survival) (NN patient) (NN colon) (NN cancer))))) |ET| |BS|12:Z01.542.049 50:M01.643 516:E05.318.740.500.700 517:E01.789.200|ES| 18:1 19:1 69:1 72:1 113:1 115:1 120:1 132:1 185:1 274:1 696:1 883:1 884:1 1810:1 1811:1 1812:1 1813:1
1 	|BT| (NP (NP (NP (DT A) (JJ novel) (NN GSK-3) (NN beta-C/EBP) (JJ alpha-miR-122-insulin-like) (NN growth) (NN factor) (CD 1) (NN receptor) (JJ regulatory) (NN circuitry)) (NP (JJ human) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 518:D08.811.913.696.620.682.725.400.185 519:D05.500.117.875|ES| 19:1 36:1 69:1 98:1 102:1 185:1 186:1 303:1 304:1 891:1 1814:1 1815:1 1816:1 1817:1 1818:1
1 	|BT| (S (NP (DT A) (JJ previous) (NN investigation)) (VP (VBD indicated) (NP (NP (NN ATA) (JJ effective) (VBG inhibiting) (NN growth) (NN breast) (NN cancer)) (NP (RB especially) (NN cell) (NN HER2) (NN overexpression))))) |ET| |BS|41:A11 45:G07.700.320.249 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 122:C14.280.383 225:E05.337 520:C10.228.140.252.190.530.060|ES| 18:1 19:1 23:1 69:1 94:1 102:1 152:1 188:1 345:1 880:1 1497:1 1541:1 1639:1 1819:1 1820:1
1 	|BT| (S (NP (JJ Additional) (NN qRT-PCR) (NN analysis)) (VP (VBD revealed) (S (NP (JJ gradual) (NN elevation) (VBG circulating) (NNS miRNAs)) (-LRB- -LRB-) (NP (FRAG (NP (FW i.e.) (, ,) (NN let-7a) (, ,) (NN let-7f) (, ,) (NN miR-34a) (, ,) (NN miR-98) (, ,) (NN miR-331) (, ,) (NN miR-338) (NN miR-652) (-RRB- -RRB-) (NN progress) (NN hepatocarcinogenesis))))))) |ET| |BS|184:D13.150.650.319 448:E05.393.620.500|ES| 2:1 10:1 14:1 19:1 275:1 661:1 876:1 888:1 900:1 1110:1 1623:1 1821:1 1822:1 1823:1 1824:1 1825:1 1826:1 1827:1 1828:1 1829:1 1830:1 1831:1
1 	|BT| (NP (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB define) (NP (NP (JJ biological) (NN contribution) (NNP Hras) (NN mouse) (NN hepatocarcinogenesis)) (, ,) (VP (VBN quantified) (S (FW vivo) (NP (NN interaction) (JJ mutant) (NNP Hras) (JJ genetic) (NN alteration)) (ADVP (RB frequently)) (VP (VBN associated) (NP (NP (NN liver) (NN cancer)) (, ,) (PP (VBG including) (NP (NP (NN overexpression) (NP (NN transcription) (NN factor) (NN c-myc) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN ligand) (VBG transforming) (NN growth) (NN factor) (NN alpha))) (PRN (-LRB- -LRB-) (NP (NN TGFalpha)) (-RRB- -RRB-))))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 64:D08.811.913.696.620.682.725.400.009.300 167:H01.158.273 170:D27.720.470.480 521:D08.811.277.040.330.300.400.500.600 522:D12.644.276.382.750 523:D12.776.260.676|ES| 2:1 10:1 14:1 18:1 19:1 52:1 102:1 104:1 152:1 169:1 184:1 185:1 186:1 378:1 440:1 455:1 487:1 561:1 618:1 698:1 811:1 828:1 836:1 864:1 900:1 951:1 959:1 1360:1 1772:1 1832:1 1833:1 1834:1 1835:1 1836:1 1837:1
1 	|BT| (S (NP (NN Alteration) (NN Apc) (NN gene)) (VP (VBN shown) (NP (NP (NN play) (JJ important) (NN role)) (JJ PhIP-induced) (JJ IQ-induced) (NN rat) (NN colon) (NN carcinogenesis)))) |ET| |BS|3:C04.557.470.035.215.100 15:F01.829.316.616 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 9:1 19:1 31:1 113:1 207:1 237:1 238:1 280:1 849:1 902:1 1838:1 1839:1 1840:1
1 	|BT| (NP (NNS Alterations) (NP (NP (NN hMSH2) (NN gene)) (VP (VBN linked) (NP (ADJP (QP (RB approximately) (CD 60)) (NN %)) (JJ hereditary) (JJ nonpolyposis) (NN colon) (NN cancer) (NN case))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 524:C04.588.274.476.411.307.190|ES| 9:1 18:1 19:1 113:1 369:1 934:1 1363:1 1841:1 1842:1 1843:1 1844:1 1845:1 1846:1
1 	|BT| (FRAG (SBAR (IN Although) (NP (NP (NP (VBN induced) (NN cell) (NN death)) (VBN regarded) (JJ major) (NN component) (NN p53) (JJ tumor-suppressive) (NN activity)) (, ,) (S (ADVP (RB recently)) (VP (VBD found) (SBAR (S (NP (JJ sustained) (NN p53) (NN activation) (JJ subsequent) (NN DNA) (NN damage)) (VP (VBZ promotes) (NP (JJ inflammation-associated) (NN hepatocarcinogenesis)))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 134:G04.299.139 525:C23.550.470 526:G05.355.180|ES| 2:1 12:1 19:1 37:1 94:1 107:1 177:1 225:1 298:1 399:1 411:1 412:1 462:1 666:1 772:1 900:1 1021:1 1319:1 1521:1 1847:1 1848:1 1849:1
1 	|BT| (NP (NP (NP (NN Amplification) (NN HER2)) (PRN (-LRB- -LRB-) (NP (NP (NN ErbB2)) (, ,) (NP (NN c-Neu))) (-RRB- -RRB-))) (NP (NP (NN proto-oncogene) (NN breast) (NN cancer)) (NP (VBN associated) (JJ poor) (NN prognosis) (JJ high) (NN relapse) (NN rate)))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 159:I01.880.735.634 163:E01.789 235:G05.360.340.024.340.375.500.791 527:C23.550.291.937|ES| 2:1 10:1 14:1 18:1 19:1 23:1 41:1 169:1 178:1 188:1 544:1 545:1 563:1 1012:1 1705:1 1850:1 1851:1
1 	|BT| (S (NP (NP (NN Androgen) (JJ receptor-induced) (NN tumor) (NN suppressor)) (, ,) (NP (NN KLLN)) (, ,)) (VP (VBZ inhibits) (SBAR (S (NP (NN breast) (NN cancer) (NN growth)) (ADVP (RB transcriptionally)) (VP (VBZ activates) (NP (JJ p53/p73-mediated) (NN apoptosis) (NN breast) (NN carcinoma))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 45:G07.700.320.249 122:C14.280.383 206:G05.360.340.024.340.375.249 528:D12.776.826.750.150|ES| 2:1 7:1 18:1 19:1 23:1 89:1 102:1 301:1 304:1 615:1 700:1 1478:1 1852:1 1853:1 1854:1 1855:1
1 	|BT| (NP (NP (NN Antitumor) (NN function) (NN microRNA-122) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 184:D13.150.650.319|ES| 19:1 33:1 303:1 304:1 1856:1 1857:1
1 	|BT| (S (NP (NN Astrocyte) (JJ elevated) (NN gene-1) (NN c-Myc)) (VP (VBP cooperate) (VP (VBP promote) (NP (NN hepatocarcinogenesis) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 529:A08.637.200|ES| 19:1 52:1 474:1 679:1 756:1 824:1 900:1 1858:1 1859:1
1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (SBAR (: :) (S (S (NP (NNS Mutations) (NN APC) (NN gene)) (VP (VBP result) (VP (VBN increased) (S (NP (NN propensity)) (VP (VB develop) (NP (JJ intestinal) (NN neoplasia))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (JJ complete) (NN understanding) (NN mechanism)) (VP (VBG resulting) (NP (NN tumor) (NN formation)))) (VP (VBD remained) (ADJP (JJ elusive))))))) |ET| |BS|8:C04 18:G05.365.590 20:G03.495 21:G05.360.340.024.340.375.249.050 30:Z01.058.290.190.800 31:D08.811.520.224.800 102:C04.588.274.476.411 239:F02.463.188.357|ES| 2:1 7:1 9:1 11:1 19:1 43:1 47:1 101:1 104:1 109:1 162:1 172:1 217:1 384:1 640:1 648:1 777:1 905:1 1046:1 1387:1 1410:1 1777:1 1778:1 1860:1 1861:1
1 	|BT| (S (SBAR (IN Because) (S (NP (NN Notch) (NN signaling) (VBN implicated) (NN colon) (NN cancer) (NN tumorigenesis)) (VP (VBZ protects) (NP (NP (NN cell) (NN apoptosis)) (VP (VBG inducing) (NP (JJ prosurvival) (NN target))))))) (, ,) (VP (VBD hypothesized) (SBAR (S (NP (NP (NN inhibition) (NN Notch) (NN signaling) (NN gamma-secretase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN GSI)) (-RRB- -RRB-))) (VP (MD may) (NP (VB enhance) (NP (NN chemosensitivity) (NN colon) (NN cancer) (NN cell)))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 43:F01.145.544 69:G02.111.087.800 125:D08.811.277.656.300.032|ES| 2:1 10:1 14:1 18:1 19:1 78:1 89:1 94:1 103:1 113:1 160:1 195:1 256:1 380:1 386:1 491:1 977:1 1690:1 1750:1 1862:1 1863:1 1864:1 1865:1 1866:1 1867:1
1 	|BT| (S (PP (IN By) (NP (JJ immunohistochemical) (NN analysis))) (, ,) (NP (CD 20) (CD 38) (NN case) (JJ undifferentiated) (NN type)) (VP (VBD advanced) (NP (NP (NN stomach) (NN cancer) (NN K-sam)) (JJ positive)) (, ,) (PP (IN whereas) (NP (NP (NN none) (CD 11) (NN case)) (SBAR (S (NP (VBN differentiated) (JJ intestinal) (NN type)) (VP (VBD revealed) (NP (NN K-sam) (NN staining))))))))) |ET| |BS|47:A03.556.124 74:G04.299.151 232:D02.886.030.676.180|ES| 2:1 18:1 19:1 109:1 233:1 275:1 372:1 543:1 661:1 782:1 801:1 803:1 804:1 934:1 997:1 1057:1 1167:1 1605:1 1868:1 1869:1 1870:1 1871:1
1 	|BT| (S (ADVP (RB Collectively)) (, ,) (NP (NN miR-122) (NN depletion)) (VP (VBZ facilitates) (NP (NP (NN cystogenesis) (NN hepatocarcinogenesis) (NN mouse) (NN DEN) (NN challenge)) (VP (VBG up-regulating) (NP (NP (JJ several) (NN gene)) (VP (VBN involved) (NP (NP (NN proliferation)) (, ,) (NP (NN growth) (NN factor) (NN signaling)) (, ,) (NP (NN neovascularization)) (, ,) (NP (NN metastasis))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 113:C04.697.650 150:Z01.542.248.960 344:M01.438 530:C23.550.589.500|ES| 2:1 9:1 19:1 52:1 102:1 185:1 195:1 262:1 299:1 774:1 806:1 900:1 1371:1 1613:1 1789:1 1872:1 1873:1 1874:1 1875:1 1876:1 1877:1
1 	|BT| (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN loss) (JJ multifunctional) (NN miR-122)) (VP (VBZ contributes) (NP (NP (JJ malignant) (NN phenotype) (NN HCC) (NN cell)) (, ,) (NP (NN miR-122) (JJ mimetic) (RB alone) (NP (NN combination) (JJ anticancer) (NN drug))) (NP (JJ promising) (JJ therapeutic) (NN regimen) (NN liver) (NN cancer))))))))) |ET| |BS|41:A11 52:E02 67:D26 80:G05.695 104:C04.557.470.200.025.255 231:C04.557.465.625.600.380.590 242:A03.620 531:E02.183.750 532:E02.183|ES| 2:1 18:1 19:1 32:1 94:1 101:1 191:1 236:1 241:1 441:1 530:1 541:1 796:1 802:1 836:1 845:1 1517:1 1789:1 1872:1 1878:1 1879:1 1880:1 1881:1
1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (DT The) (NN outcome) (NN study)) (VP (VBP represent) (NP (JJ significant) (NN contribution) (JJ current) (NN understanding) (JJ preventive) (NN mechanism) (NN quercetin) (JJ early) (NN stage) (NN liver) (NN cancer) (NN development)) (, ,) (S (VP (VBG demonstrating) (NP (NP (NN addition)) (VP (VBN known) (VP (JJ proapoptotic) (ADJP (ADJP (JJ characteristic)) (, ,) (SBAR (S (NP (NN flavonoid)) (VP (VBZ modulates) (NP (NP (NN expression) (JJ critical) (NN cell) (NN cycle) (NN regulator)) (NN peroxisome) (NN proliferator) (VBD activated) (NN receptor-alpha) (NN activity)))))))))))))) |ET| |BS|239:F02.463.188.357 242:A03.620 353:G04.299.134 473:E01.789.625 533:D03.383.663.283.266.450.284.777 534:D03.383.663.283.266.450 535:H01.770.644.145.431 536:D12.776.826.239.500|ES| 2:1 18:1 19:1 35:1 94:1 104:1 115:1 131:1 135:1 162:1 163:1 175:1 235:1 336:1 399:1 468:1 527:1 547:1 556:1 601:1 606:1 691:1 799:1 825:1 836:1 905:1 1128:1 1129:1 1360:1 1882:1 1883:1 1884:1 1885:1 1886:1 1887:1 1888:1 1889:1
1 	|BT| (S (NP (NN CONCLUSION) (: :)) (NP (DT These) (JJ clinical) (JJ mechanistic) (NN finding)) (VP (VBP indicate) (SBAR (S (NP (NP (NN IFITM3) (JJ direct) (JJ transcriptional) (NN target) (NN KLF4)) (VBN dysregulated) (NP (NN KLF4)) (NN expression)) (VP (VBP lead) (NP (JJ aberrant) (NN IFITM3) (NN expression)) (, ,) (S (ADVP (RB thus)) (VP (VBG contributing) (NP (NN colon) (NN cancer) (NN progression) (NN metastasis))))))))) |ET| |BS|16:C23.550.291.656 86:D01.268.556.435 113:C04.697.650 209:G02.111.087.847|ES| 2:1 18:1 19:1 48:1 84:1 104:1 113:1 115:1 160:1 254:1 559:1 696:1 792:1 806:1 927:1 1259:1 1295:1 1334:1 1479:1 1725:1 1882:1 1890:1 1891:1 1892:1
1 	|BT| (NP (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (JJ Acute) (NN ablation) (NN GSK3beta) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ activates) (NP (JJ p53-dependent) (NN apoptosis)))) (SBAR (S (VP (VBZ antagonizes) (NP (NN tumor) (NN growth))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 39:G04.299.139.160 41:A11 45:G07.700.320.249|ES| 7:1 17:1 18:1 19:1 88:1 89:1 91:1 94:1 102:1 104:1 239:1 301:1 794:1 1893:1 1894:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (PRP$ Our) (NN result)) (VP (VB identify) (NP (NP (NP (JJ novel) (NN candidate) (NN mouse) (NN gene)) (, ,) (NP (NN Zfp277)) (, ,)) (SBAR (WHNP (WP$ whose) (NN expression) (NN pattern)) (S (NP (JJ compatible) (NN role)) (VP (VBG mediating) (NP (JJ divergent) (NN effect) (NN Chrm3) (NN Chrm1) (NN gene) (NN ablation) (JJ murine) (JJ intestinal) (NN neoplasia))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 47:A03.556.124 102:C04.588.274.476.411 259:D12.776.395.240.150.500 537:G05.360.340.024.340.375|ES| 2:1 9:1 19:1 31:1 52:1 75:1 91:1 101:1 104:1 109:1 115:1 239:1 260:1 627:1 640:1 658:1 761:1 832:1 891:1 919:1 1243:1 1895:1 1896:1 1897:1 1898:1 1899:1
1 	|BT| (S (NP (NN CRC)) (VP (VBD initiated) (NP (NP (NN mutation) (NN tumor) (NN suppressor) (NN gene)) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-))) (, ,) (NP (NN beta-catenin) (NN gene)))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 18:G05.365.590 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 206:G05.360.340.024.340.375.249|ES| 2:1 7:1 9:1 10:1 11:1 14:1 19:1 34:1 57:1 58:1 59:1 60:1 245:1 700:1 1900:1
1 	|BT| (S (NP (NN CRC) (NN xenograft)) (VP (VBD differed) (NP (NP (NP (NP (NN p53) (NN status)) (PRN (-LRB- -LRB-) (NP (JJ wt) (NN muf)) (-RRB- -RRB-))) (NN microsatellite) (NN instability) (NN phenotype)) (PRN (-LRB- -LRB-) (NP (NP (NN MSI)) (CC +) (NP (JJ altered))) (-RRB- -RRB-))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 80:G05.695 92:E04.936.764 93:A01.941.875 538:C23.550.362.590|ES| 10:1 12:1 14:1 19:1 236:1 245:1 265:1 416:1 693:1 1299:1 1332:1 1901:1 1902:1 1903:1 1904:1
1 	|BT| (NP (NP (JJ Differential) (NN effect) (JJ oncogenic) (NN K-Ras) (NN N-Ras) (NN proliferation)) (, ,) (NP (NN differentiation) (NN tumor) (NN progression) (NN colon))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 16:C23.550.291.656 51:C04.588.274.476.411.307.180 74:G04.299.151 279:D27.888.569.100|ES| 2:1 7:1 13:1 19:1 48:1 75:1 113:1 215:1 299:1 953:1 1905:1 1906:1
1 	|BT| (S (NP (NN Differentiation) (NN therapy) (JJ hepatocellular) (NN carcinoma) (NN mouse) (JJ recombinant) (NN adenovirus)) (VP (VBG carrying) (NP (NN hepatocyte) (JJ nuclear) (NN factor-4alpha) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 52:E02 74:G04.299.151 104:C04.557.470.200.025.255 247:G01.374.676.530 539:D20.215.894.899.024 540:D12.776.260.262 541:C02.256.076 542:B04.280.030|ES| 9:1 19:1 52:1 130:1 303:1 304:1 850:1 1256:1 1420:1 1907:1 1908:1 1909:1 1910:1
1 	|BT| (S (S (NP (JJ Ectopic) (NN expression) (NN miR-155)) (VP (VBD promoted) (NP (NP (NP (NN growth) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN cell)))) (, ,) (IN whereas) (S (NP (NN depletion)) (VP (VBD inhibited) (NP (NN cell) (NN growth))))) |ET| |BS|41:A11 45:G07.700.320.249 104:C04.557.470.200.025.255 107:G05.355.315.202 122:C14.280.383|ES| 2:1 10:1 14:1 19:1 94:1 102:1 115:1 303:1 304:1 305:1 365:1 372:1 441:1 1613:1 1911:1 1912:1
1 	|BT| (S (NP (JJ Ectopic) (NN reactivation) (NN miR-184)) (VP (VBD inhibited) (SBAR (S (NP (NP (NN proliferation) (NP (NP (JJ self-renewal) (JJ triple) (JJ negative) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN TNBC)) (-RRB- -RRB-))) (NN cell) (NN line) (NN vitro)) (VP (VBN delayed) (NP (JJ primary) (NN tumour) (NN formation)))) (VP (VBD reduced) (NP (JJ metastatic) (NN burden) (FW vivo))))))) |ET| |BS|8:C04 20:G03.495 122:C14.280.383 160:C04.588.180.788 543:G04.299.134.220.235|ES| 10:1 14:1 18:1 19:1 23:1 43:1 94:1 216:1 264:1 299:1 305:1 337:1 344:1 365:1 378:1 449:1 452:1 537:1 1011:1 1716:1 1913:1 1914:1 1915:1 1916:1 1917:1
1 	|BT| (NP (NP (JJ Epigenetic) (NN inactivation) (JJ paired) (NN box) (NN gene) (CD 5)) (, ,) (NP (JJ novel) (NN tumor) (NN suppressor) (NN gene)) (, ,) (NP (NP (JJ direct) (NN upregulation) (NN p53)) (NP (VBN associated) (NN prognosis) (JJ gastric) (NN cancer) (NN patient)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 42:G05.355.315.203.374 50:M01.643 163:E01.789 206:G05.360.340.024.340.375.249 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880|ES| 2:1 7:1 9:1 12:1 18:1 19:1 86:1 120:1 169:1 544:1 578:1 700:1 790:1 891:1 1126:1 1201:1 1314:1 1891:1 1918:1
1 	|BT| (NP (NP (NP (NN ERBB4) (NN alteration)) (NP (NP (NP (DT The) (NN Cancer) (NNP Genome) (NNP Atlas) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NP (NP (NN data) (NN set) (JJ stratified) (NN survival)) (, ,) (VP (VBN combined) (S (NP (NNP Moffitt) (NNP Cancer) (NNP Center) (NNP Vanderbilt) (NNP Medical) (NNP Center) (NN CRC) (NN expression) (NNS data)) (VP (VBN set) (, ,) (SBAR (S (NP (NN ERBB4) (NN message) (NN level)) (VP (VBD increased) (NP (NN tumor) (NN stage)))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 96:I03.784 97:V02.302 269:G05.360.340 544:A02.835.232.834.151.500 545:F02.463.425.838 546:V02.150|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 47:1 115:1 164:1 245:1 249:1 274:1 691:1 793:1 951:1 1129:1 1679:1 1919:1 1920:1 1921:1 1922:1 1923:1 1924:1 1925:1 1926:1 1927:1 1928:1
1 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN Apo-FHL2) (NN mouse)) (VP (VBD developed) (SBAR (S (NP (NP (NN tumor)) (, ,) (NP (NN FHL2) (NN transgene))) (VP (VBD enhanced) (SBAR (S (NP (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ liver-specific) (NN deletion) (NP (NP (JJ adenomatous) (NN polyposis) (NN coli) (NN gene) (JJ aberrant) (NN Wnt/beta-catenin) (NN signaling) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN lox/lox)) (-RRB- -RRB-))) (NN animal)))))))))) |ET| |BS|3:C04.557.470.035.215.100 8:C04 11:B01.050.150.900.649.865.635.505.500 19:B01.050 21:G05.360.340.024.340.375.249.050 105:G02.149.115.800.925 242:A03.620 547:G05.360.340.024.340.825 548:D08.811.682.664.500.848 549:G05.355.600.800.320|ES| 2:1 7:1 9:1 10:1 14:1 19:1 46:1 52:1 57:1 58:1 59:1 195:1 280:1 302:1 385:1 412:1 900:1 1059:1 1165:1 1725:1 1799:1 1929:1 1930:1 1931:1 1932:1 1933:1
1 	|BT| (S (NP (JJ Further) (NN study) (NN mechanism) (NN ADCY3) (NN tumorigenesis)) (VP (VBP provide) (NP (NN basis) (JJ new) (JJ molecular) (NN target) (JJ gastric) (NN cancer)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098|ES| 18:1 19:1 78:1 86:1 131:1 160:1 161:1 162:1 330:1 711:1 712:1 1140:1 1934:1
1 	|BT| (S (ADVP (RB Furthermore)) (NP (NP (NN strategy)) (VP (VBN designed) (VP (VB restore) (NP (NN expression) (NN PTEN))))) (VP (MD may) (S (VP (VBG promising) (NP (NP (NN therapy)) (VP (VBG preventing) (NP (NN HCV) (JJ dependent) (NN hepatocarcinogenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 550:B04.450.410|ES| 19:1 115:1 130:1 321:1 334:1 491:1 900:1 1114:1 1517:1 1683:1 1935:1 1936:1 1937:1 1938:1
1 	|BT| (S (NP (NN Germ-line) (NN mutation) (NN APC) (NN gene)) (VP (NN cause) (SBAR (S (NP (NP (JJ adenomatous) (NN polyposis) (NN coli) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))) (, ,) (NP (NN syndrome) (NN patient))) (VP (VBP develop) (NP (CD hundred) (CD thousand) (JJ precancerous) (JJ adenomatous) (JJ colorectal) (NN polyp))))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 50:M01.643 341:C04.834 551:C04.557.470.035.215 552:G05.365.590.350 553:C23.550.288.500|ES| 2:1 9:1 10:1 11:1 14:1 17:1 19:1 34:1 57:1 58:1 59:1 120:1 647:1 648:1 1130:1 1779:1 1939:1 1940:1 1941:1 1942:1
1 	|BT| (S (S (ADVP (RB Hence)) (, ,) (NP (NN agent)) (VP (VBD prevented) (SBAR (S (NP (NN colon) (NN cancer)) (VP (VBD decreased) (NP (NP (JJ mitotic) (NN index)) (NP (VBN altered) (NN expression) (NN c-myc)))))))) (, ,) (NP (NN p16) (NN p27)) (VP (VBG suggesting) (NP (NP (NN modulation) (NN expression) (NN gene)) (JJ potential) (NNS biomarkers) (JJ chemopreventive) (NN activity)))) |ET| |BS|155:G05.355.310 158:D23.101 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500|ES| 2:1 9:1 18:1 19:1 113:1 115:1 202:1 399:1 455:1 693:1 720:1 721:1 728:1 827:1 1009:1 1124:1 1269:1 1313:1 1943:1 1944:1 1945:1 1946:1
1 	|BT| (S (NP (JJ Hepatic) (NN loss) (NN miR-122)) (VP (VBZ predisposes) (NP (NN mouse) (JJ hepatobiliary) (NN cyst) (JJ hepatocellular) (NN carcinoma)) (PP (IN upon) (NP (NN diethylnitrosamine) (NN exposure))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 554:D02.654.442.200 555:C04.182|ES| 19:1 32:1 52:1 303:1 304:1 1789:1 1947:1 1948:1 1949:1 1950:1 1951:1 1952:1 1953:1
1 	|BT| (S (NP (NNP Hepatitis) (NNP C) (JJ virus-induced) (NN up-regulation) (NN microRNA-155)) (VP (VBZ promotes) (NP (NN hepatocarcinogenesis) (VBG activating) (NN Wnt) (NN signaling)))) |ET| |BS|69:G02.111.087.800 184:D13.150.650.319 249:G05.355.315.800 339:G02.111.087.880 550:B04.450.410|ES| 19:1 195:1 298:1 877:1 896:1 900:1 1954:1 1955:1 1956:1 1957:1 1958:1
1 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (NP (NN diethylnitrosamine) (JJ hepatic) (NN deletion) (NN PTEN)))) |ET| |BS|306:G05.355.600.800 554:D02.654.442.200|ES| 19:1 412:1 838:1 1059:1 1936:1 1952:1 1959:1
1 	|BT| (NP (NP (ADJP (RB Here) (VBN studied)) (NN role) (NN HNF4alpha) (NN mechanism) (NN deregulation) (NN Cdx2) (NN colon) (NN cancer))) |ET| |BS|15:F01.829.316.616|ES| 18:1 19:1 31:1 113:1 123:1 162:1 213:1 400:1 401:1 402:1
1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBD investigated) (NP (NP (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (JJ oncogenic) (NN cooperation) (NN c-Myc) (NN E2F1) (NN relationship) (JJ human) (NN liver) (NN cancer)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100|ES| 2:1 18:1 19:1 36:1 161:1 162:1 223:1 400:1 403:1 435:1 824:1 836:1 953:1 1960:1 1961:1
1 	|BT| (S (NP (JJ Heterozygous) (NN disruption) (NN PTEN)) (VP (VBZ promotes) (NP (NP (JJ intestinal) (NN neoplasia) (NN APCmin)) (: /) (NP (CC +) (NP (NN mouse)) (: :) (NP (NN role))) (NP (NN osteopontin))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 102:C04.588.274.476.411 157:G05.380.383 350:D12.644.276.374.625|ES| 19:1 31:1 52:1 104:1 109:1 298:1 640:1 1160:1 1602:1 1936:1 1962:1 1963:1
1 	|BT| (S (NP (NN HNF4alpha) (NN Cdx2)) (ADVP (RB also)) (VP (VBD exhibited) (NP (JJ comparable) (VBN deregulated) (NN pattern) (JJ human) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 175:J01.897.280.500.269|ES| 5:1 19:1 36:1 123:1 213:1 245:1 260:1 609:1 1964:1 1965:1
1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NP (NP (NN effect) (NN HNF4alpha) (NN cancer) (NN stem) (NN cell)) (PRN (-LRB- -LRB-) (NP (NNS CSCs)) (-RRB- -RRB-))) (NP (NP (NN treatment) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN HNF4alpha)) (VP (VBD reported))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 332:A11.872.650 556:C11.768.175|ES| 2:1 10:1 14:1 18:1 19:1 75:1 94:1 123:1 303:1 304:1 433:1 441:1 546:1 993:1 1106:1 1966:1
1 	|BT| (S (ADVP (RB However)) (, ,) (SBAR (IN whether) (S (NP (NN up-regulation) (NN DLGAP5)) (VP (VBZ contributes) (NP (NN hepatocarcinogenesis))))) (VP (VBZ remains) (ADJP (JJ unclear)))) |ET| |BS|142:I01.880.604|ES| 2:1 19:1 221:1 433:1 442:1 443:1 845:1 896:1 900:1 1191:1
1 	|BT| (S (PP (IN In) (NP (NN aggregate))) (, ,) (VP (VBP conclude) (NP (NP (NP (NN Let-7) (NN depletion) (NN drive) (NN stem) (NN cell) (NN phenotype)) (NN development) (JJ intestinal) (NN cancer)) (, ,) (PP (ADVP (RB primarily)) (IN via) (NP (NN Hmga2)))))) |ET| |BS|66:F01.658.293 80:G05.695 101:C04.588.274.476.411 283:D12.776.260.312.937 308:A11.872 557:D02.241.081.069.600.150|ES| 2:1 18:1 19:1 35:1 94:1 109:1 181:1 236:1 244:1 596:1 1106:1 1613:1 1967:1 1968:1 1969:1 1970:1 1971:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN loss) (NN PTEN) (NN dysregulation)) (VP (VBG transforming) (NP (NP (NN growth) (NN factor) (NN beta) (NN signaling)) (VP (VBN considered) (S (NP (JJ involved) (NN rat) (NN hepatocarcinogenesis) (JJ early) (NN stage))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 503:D12.644.276.374.687|ES| 2:1 19:1 32:1 102:1 185:1 195:1 244:1 774:1 849:1 900:1 1061:1 1128:1 1129:1 1202:1 1284:1 1772:1 1936:1 1972:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN MiR-7) (JJ novel) (NN miRNA) (NN tumor) (JJ suppressive) (NN function) (NN colon) (NN cancer)) (VP (VBG targeting) (NP (JJ oncogenic) (NN YY1)))) |ET| |BS|8:C04 184:D13.150.650.319 258:D12.776.260.235.875 259:D12.776.395.240.150.500 279:D27.888.569.100|ES| 2:1 7:1 18:1 19:1 33:1 113:1 244:1 616:1 840:1 879:1 891:1 953:1 1284:1 1973:1 1974:1
1 	|BT| (NP (NP (PP (IN In) (NP (NN conclusion))) (, ,) (NP (S (VP (VBG finding) (S (VP (VBP indicate) (SBAR (S (NP (NN miR-375) (NN target) (NN AEG-1) (NN HCC)) (VP (VBZ suppresses) (NP (NN liver) (NN cancer) (NN cell) (NN growth)) (ADVP (FW vitro) (FW vivo))))))))) (, ,) (NP (NN highlight) (JJ therapeutic) (JJ potential) (NN miR-375) (NN HCC) (NN treatment))))) |ET| |BS|41:A11 45:G07.700.320.249 52:E02 104:C04.557.470.200.025.255 262:A11.436.348|ES| 2:1 18:1 19:1 94:1 102:1 160:1 216:1 244:1 378:1 441:1 541:1 546:1 686:1 827:1 836:1 927:1 1284:1 1479:1 1675:1 1975:1 1976:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN overexpression) (NN PPARgamma1) (NN gene)) (VP (VBZ exerts) (NP (NP (JJ beneficial) (NN effect)) (VP (VBG attenuating) (NP (NN atherosclerosis) (NN progression))))) (VP (VBZ stabilizes) (NP (JJ vulnerable) (NN plaque)))) |ET| |BS|6:G05.360.340.024.340 16:C23.550.291.656 511:C14.907.137.126.307 513:C14.907.137.126 558:C23.300.821|ES| 2:1 9:1 19:1 48:1 75:1 152:1 244:1 984:1 1284:1 1803:1 1804:1 1977:1 1978:1 1979:1 1980:1 1981:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NNS data)) (VP (VBP indicate) (SBAR (S (NP (NN LHX4)) (VP (MD may) (VP (VB act) (NP (JJ potential) (NN tumor) (NN suppressor) (NN hepatocarcinogenesis)) (, ,) (S (VP (VBG suggesting) (S (VP (VBG targeting) (NP (NN LHX4))))))))))) (VP (VBP downregulate) (SBAR (S (NP (NN AFP)) (VP (MD might) (NP (JJ therapeutic) (NN implication))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 81:E02.095.465.425.400.330.050.400 206:G05.360.340.024.340.375.249|ES| 2:1 7:1 19:1 85:1 244:1 246:1 491:1 508:1 541:1 616:1 700:1 793:1 798:1 827:1 900:1 1009:1 1196:1 1284:1 1479:1 1982:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN study)) (VP (VBP show) (SBAR (S (NP (NN TS) (NN gene) (NN expression) (NN pretreatment) (NN biopsy)) (VP (VBZ predicts) (NP (NN response) (JJ local) (JJ rectal) (NN cancer) (JJ neo-adjuvant) (JJ 5-FU-based) (NN chemoradiotherapy) (JJ high) (NN percentage))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 154:Z01.058.266.887 155:G05.355.310 333:D01.045 559:E01.370.225.500.384.100 560:D03.383.742.698.875.404 561:E02.186.079.500|ES| 2:1 9:1 18:1 19:1 115:1 131:1 178:1 244:1 429:1 494:1 509:1 1284:1 1751:1 1983:1 1984:1 1985:1 1986:1 1987:1 1988:1 1989:1 1990:1
1 	|BT| (NP (NP (PP (IN In) (NP (VBN damaged) (NN tissue))) (, ,) (NP (NP (JJ combined) (NN loss) (NN RB) (NN p53)) (VBD resulted) (NP (JJ early) (NN lesion) (NN formation)) (, ,) (NP (NP (JJ aggressive) (NN tumor) (NN progression)) (, ,) (NP (NP (NN gene) (NN expression) (NN signature)) (NP (JJ histologic) (JJ characteristic) (JJ advanced) (JJ human) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 16:C23.550.291.656 20:G03.495 98:A10 104:C04.557.470.200.025.255 162:F01.145.126.125 384:G02.111.087.847.750 562:F01.510|ES| 2:1 7:1 9:1 12:1 19:1 32:1 36:1 43:1 48:1 115:1 164:1 244:1 272:1 303:1 304:1 336:1 538:1 594:1 997:1 1128:1 1131:1 1209:1 1230:1 1991:1 1992:1
1 	|BT| (FRAG (PP (IN In) (NP (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (NN model) (NN colon) (NN cancer))) (, ,) (NP (NP (NN addition) (NN K-ras) (NN mutation)) (, ,) (VP (VBN shown) (S (NP (ADJP (ADJP (JJ wild-type)) (PRN (-LRB- -LRB-) (ADJP (JJ WT)) (-RRB- -RRB-))) (NN Ras)) (VP (VBD activated) (NP (NP (JJ upstream) (NN pathway)) (, ,) (S (VBG including) (, ,) (PP (FW e.g.)) (, ,) (VP (VBG signaling) (NP (NN ErbB) (NN receptor)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 69:G02.111.087.800 132:D02.172.080 563:D08.811.913.696.620.682.725.400.009|ES| 2:1 8:1 10:1 14:1 18:1 19:1 34:1 72:1 113:1 163:1 186:1 195:1 237:1 244:1 383:1 468:1 561:1 1121:1 1775:1 1993:1 1994:1 1995:1 1996:1 1997:1 1998:1
1 	|BT| (FRAG (PP (IN In) (NP (NN context))) (, ,) (NP (NP (NP (NN study) (NN p53)) (NP (ADVP (RB therefore)) (NP (JJ obvious) (NN implication) (JJ human) (NN health) (NN performance)))) (, ,) (NP (NP (VBN given) (JJ impaired) (JJ mitochondrial) (NN content) (NN function)) (VBN associated) (NN pathology) (JJ many) (JJ metabolic) (NN disorder)) (NP (JJ ageing) (, ,) (NN type) (CD 2) (NN diabetes)) (, ,) (NP (NN obesity) (NN cancer)) (, ,) (NP (ADJP (RB well) (VBN reduced)) (NN exercise) (NN performance)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 55:B01.050.150.900.649.801.400.112.400.400 564:C18.654.726.500 565:A11.284.430.214.190.875.564 566:G11.427.590.530.698.277 567:G05.360.340.024.340.365 568:C18.452.394.750.149 569:G07.700.320.124 570:C23.550 571:N01.400|ES| 2:1 12:1 18:1 19:1 29:1 33:1 36:1 85:1 131:1 148:1 169:1 218:1 244:1 452:1 543:1 787:1 1040:1 1794:1 1999:1 2000:1 2001:1 2002:1 2003:1 2004:1 2005:1 2006:1 2007:1 2008:1 2009:1 2010:1 2011:1
1 	|BT| (S (PP (IN In) (NP (NN report))) (, ,) (VP (VBP show) (NP (NP (NP (NP (JJ synergistic) (NN action) (NN HBx) (NN p53) (NN mutation) (NN trigger) (JJ progressive) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN formation)) (PP (IN via) (NP (NN src) (NN activation) (NN zebrafish)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 18:G05.365.590 20:G03.495 104:C04.557.470.200.025.255 572:B01.050.150.900.493.200.244.828 573:N05.715.350.200.650|ES| 2:1 10:1 12:1 14:1 19:1 34:1 43:1 225:1 244:1 303:1 304:1 417:1 429:1 441:1 596:1 610:1 2012:1 2013:1 2014:1 2015:1 2016:1 2017:1
1 	|BT| (S (NP (NN Inactivation) (NN APC) (NN gene)) (VP (VBN considered) (S (VP (VBG initiating) (NP (NN event) (JJ human) (JJ colorectal) (NN cancer)))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 42:G05.355.315.203.374 55:B01.050.150.900.649.801.400.112.400.400|ES| 9:1 11:1 17:1 18:1 19:1 36:1 205:1 1061:1 2018:1 2019:1
1 	|BT| (S (NP (NN Induction) (NN p53)) (VP (VBP render) (NP (JJ ATM-deficient) (NN mouse) (JJ refractory) (NN hepatocarcinogenesis)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500|ES| 12:1 19:1 52:1 900:1 2020:1 2021:1 2022:1 2023:1
1 	|BT| (S (NP (NNP Integrated) (JJ transcriptomic) (JJ genomic) (NN analysis)) (VP (VBN defined) (S (NP (NP (JJ distinct) (NN superenhancer) (NN CIMP)) (CC +) (NP (NN colon) (NN cancer))) (VP (VBZ regulates) (NP (NN cMYC) (NN transcription)))))) |ET| |BS|209:G02.111.087.847 268:H01.158.273.180.350 269:G05.360.340|ES| 18:1 19:1 113:1 487:1 603:1 661:1 680:1 910:1 2024:1 2025:1 2026:1 2027:1 2028:1 2029:1
1 	|BT| (S (NP (JJ Intestinal) (NN cancer)) (VP (VBN driven) (SBAR (S (NP (ADJP (RB purely) (NN PTEN-deficiency)) (JJ transgenic) (NN mouse)) (VP (VBD developed) (NP (NP (NN CM) (JJ human) (NN CRC)) (, ,) (NP (NP (NN CM)) (VP (VBN associated) (NP (NNP PTEN) (NNP PRKCZ) (NN readout)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 66:F01.658.293 87:C18.654.521 99:B01.050.050.136.500 101:C04.588.274.476.411|ES| 2:1 18:1 19:1 36:1 52:1 169:1 204:1 245:1 285:1 920:1 1165:1 1936:1 2030:1 2031:1 2032:1 2033:1 2034:1
1 	|BT| (S (NP (JJ Isogenic) (JJ LKB1-knockdown) (NN breast) (NN cancer) (NN cell) (NN line) (NN pair)) (VP (VBD developed))) |ET| |BS|94:A11.251.210|ES| 18:1 19:1 23:1 94:1 264:1 1165:1 2035:1 2036:1 2037:1
1 	|BT| (S (NP (NN ITF-2)) (VP (VP (VBD disrupted) (PP (IN via) (NP (JJ allelic) (NN loss) (NN chromosome) (NN 18q21)))) (, ,) (SBAR (S (NP (NN ITF-2B) (NN expression)) (VP (VBD lost) (NP (JJ adenoma-carcinoma) (NN transition))))))) |ET| |BS|17:C04.557.470.035 289:A11.284.187 290:G05.365.590.029.530 317:C04.557.470.200.430|ES| 2:1 19:1 32:1 115:1 552:1 596:1 1005:1 1475:1 2038:1 2039:1 2040:1 2041:1 2042:1 2043:1
1 	|BT| (S (NP (JJ K-ras) (NN mutation)) (VP (VBP occur) (ADVP (RB frequently)) (S (NP (NN colon) (NN cancer)) (VP (VBP contribute) (NP (JJ autonomous) (NN growth)))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 45:G07.700.320.249|ES| 18:1 19:1 34:1 102:1 113:1 450:1 698:1 1121:1 2044:1 2045:1
1 	|BT| (NP (NP (JJ Many) (JJ etiological) (NN factor)) (, ,) (PP (VBG including) (NP (NP (NP (NP (NN hepatitis) (NN B) (NN virus) (NN X) (NN antigen)) (PRN (-LRB- -LRB-) (NP (NN HBx)) (-RRB- -RRB-))) (NN p53) (NN mutation)) (, ,) (NP (VBN implicated) (NN hepatocarcinogenesis))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 18:G05.365.590 73:N05.715.350.200|ES| 2:1 10:1 12:1 14:1 19:1 34:1 185:1 561:1 763:1 900:1 929:1 977:1 1030:1 1422:1 2014:1 2046:1 2047:1 2048:1
1 	|BT| (S (NP (NNS Mice)) (NP (JJ heterozygous) (JJ dominant) (NN Min) (NN mutation) (NN Apc) (NN gene)) (VP (VBP develop) (NP (JJ multiple) (JJ intestinal) (NN neoplasia)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 102:C04.588.274.476.411 157:G05.380.383|ES| 9:1 19:1 34:1 109:1 280:1 583:1 640:1 648:1 649:1 650:1 786:1 2049:1
1 	|BT| (NP (NP (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NP (NN methionine) (NN adenosyltransferase) (NN 1A)) (PRN (-LRB- -LRB-) (NP (NN MAT1A)) (-RRB- -RRB-))))) (VP (VBD reduced) (NP (NN PHB1) (NN expression)))) (, ,) (JJ impaired) (JJ mitochondrial) (NN function)) (, ,) (VP (ADVP (RB spontaneously)) (VB develop) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 574:D08.811.913.225.650|ES| 2:1 10:1 14:1 19:1 33:1 115:1 303:1 304:1 376:1 441:1 452:1 583:1 648:1 1506:1 1792:1 2003:1 2004:1 2050:1 2051:1 2052:1 2053:1
1 	|BT| (S (NP (NN MicroRNA) (NNP 301A)) (VP (VBZ Promotes) (NP (NP (JJ Intestinal) (NN Inflammation) (NNP Colitis-Associated) (NNP Cancer) (NNP Development)) (VP (VBG Inhibiting) (NP (NN BTG1)))))) |ET| |BS|47:A03.556.124 53:C06.405.205.265 122:C14.280.383 184:D13.150.650.319 525:C23.550.470|ES| 19:1 204:1 1919:1 2054:1 2055:1 2056:1 2057:1 2058:1 2059:1 2060:1 2061:1
1 	|BT| (S (NP (NN MicroRNA-122)) (VP (VBZ inhibits) (SBAR (S (NP (JJ tumorigenic) (NN property) (JJ hepatocellular) (NN carcinoma) (NN cell)) (VP (VBZ sensitizes) (NP (NN cell) (NN sorafenib))))))) |ET| |BS|41:A11 104:C04.557.470.200.025.255 122:C14.280.383 184:D13.150.650.319 575:V02.050|ES| 19:1 94:1 303:1 304:1 615:1 841:1 1797:1 1809:1 2062:1 2063:1
1 	|BT| (S (NP (NN microRNA-146a)) (VP (VBZ inhibits) (NP (NP (NN cancer) (NN metastasis)) (VP (VBG downregulating) (NP (NN VEGF) (JJ dual) (NN pathway) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|104:C04.557.470.200.025.255 113:C04.697.650 122:C14.280.383 184:D13.150.650.319|ES| 18:1 19:1 303:1 304:1 383:1 615:1 806:1 2064:1 2065:1 2066:1 2067:1
1 	|BT| (NP (NP (NP (NN MicroRNA-21) (JJ potential) (NN link) (JJ non-alcoholic) (NN fatty) (NN liver) (NN disease) (JJ hepatocellular) (NN carcinoma)) (PP (IN via) (NP (NN modulation) (NN HBP1-p53-Srebp1c) (NN pathway))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 104:C04.557.470.200.025.255 184:D13.150.650.319 576:D12.776.260.103.500.750.500 577:C06.552.241.519|ES| 19:1 303:1 304:1 383:1 596:1 827:1 836:1 998:1 1608:1 1945:1 2068:1 2069:1 2070:1 2071:1
1 	|BT| (S (NP (NN MicroRNA-221)) (VP (VBZ governs) (S (NP (NN tumor) (NN suppressor) (NN HDAC6)) (VP (VB potentiate) (NP (JJ malignant) (NN progression) (NN liver) (NN cancer)))))) |ET| |BS|16:C23.550.291.656 30:Z01.058.290.190.800 31:D08.811.520.224.800 184:D13.150.650.319 206:G05.360.340.024.340.375.249 231:C04.557.465.625.600.380.590|ES| 7:1 18:1 19:1 48:1 700:1 802:1 836:1 2072:1 2073:1 2074:1 2075:1
1 	|BT| (S (NP (NN MicroRNA-375) (NN target) (NN AEG-1) (JJ hepatocellular) (NN carcinoma)) (VP (VBZ suppresses) (NP (NN liver) (NN cancer) (NN cell) (NN growth)) (ADVP (FW vitro) (FW vivo)))) |ET| |BS|41:A11 45:G07.700.320.249 104:C04.557.470.200.025.255 184:D13.150.650.319 262:A11.436.348|ES| 18:1 19:1 94:1 102:1 160:1 216:1 303:1 304:1 378:1 686:1 836:1 1976:1 2076:1
1 	|BT| (S (NP (NN MicroRNA-608)) (VP (VBZ inhibits) (NP (NN proliferation) (NN bladder) (NN cancer)) (PP (IN via) (NP (NP (NN AKT/FOXO3a)) (NN signaling) (NN pathway))))) |ET| |BS|69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 184:D13.150.650.319 378:D08.811.913.696.620.682.700.755|ES| 18:1 19:1 195:1 299:1 383:1 564:1 596:1 615:1 2077:1 2078:1
1 	|BT| (S (NP (NN MicroRNA-7)) (VP (VBZ inhibits) (NP (NP (NN tumor) (NN growth) (NN metastasis)) (VP (VBG targeting) (NP (NN phosphoinositide) (NN 3-kinase/Akt) (NN pathway) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|8:C04 45:G07.700.320.249 104:C04.557.470.200.025.255 113:C04.697.650 122:C14.280.383 184:D13.150.650.319 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550|ES| 7:1 19:1 102:1 303:1 304:1 383:1 615:1 616:1 806:1 2079:1 2080:1 2081:1
1 	|BT| (NP (NP (NN Microsatellite) (NN instability) (NN tool) (NN classification) (JJ gastric) (NN cancer))) |ET| |BS|395:L01.100 538:C23.550.362.590|ES| 18:1 19:1 86:1 831:1 1299:1 1338:1 2082:1
1 	|BT| (S (NP (JJ Microsomal) (NN prostaglandin) (NN E) (NN synthase-1)) (VP (VBN involved) (NP (JJ multiple) (NN step) (NN colon) (NN carcinogenesis)))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356|ES| 19:1 113:1 207:1 649:1 774:1 2083:1 2084:1 2085:1 2086:1 2087:1
1 	|BT| (S (NP (JJ Microsomal) (NN prostaglandin) (NN E) (NN synthase-1)) (VP (VBZ promotes) (NP (NN hepatocarcinogenesis) (NN activation) (JJ novel) (NN EGR1/beta-catenin) (NN signaling) (NN axis)))) |ET| |BS|23:D12.776.091.249 69:G02.111.087.800 259:D12.776.395.240.150.500 579:A02.835.232.834.151.383 580:D12.776.260.158.500|ES| 19:1 195:1 225:1 298:1 891:1 900:1 2083:1 2084:1 2085:1 2086:1 2088:1 2089:1
1 	|BT| (S (NP (NN MiR-122)) (VP (VBZ inhibits) (NP (NP (NN cell) (NN proliferation) (NN tumorigenesis) (NN breast) (NN cancer)) (VP (VBG targeting) (NP (NN IGF1R)))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 122:C14.280.383 183:G04.299.233.750|ES| 18:1 19:1 23:1 78:1 94:1 299:1 615:1 616:1 2090:1 2091:1
1 	|BT| (S (NP (NN MiR-145)) (VP (VBZ modulates) (NP (JJ multiple) (NN component) (JJ insulin-like) (NN growth) (NN factor) (NN pathway) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|104:C04.557.470.200.025.255 581:D12.644.276.937|ES| 19:1 102:1 185:1 303:1 304:1 383:1 606:1 649:1 1021:1 2092:1 2093:1
1 	|BT| (S (NP (NN miR-185)) (VP (VBZ inhibits) (NP (NP (JJ hepatocellular) (NN carcinoma) (NN growth)) (VP (VBG targeting) (NP (NN DNMT1/PTEN/Akt) (NN pathway)))))) |ET| |BS|45:G07.700.320.249 104:C04.557.470.200.025.255 122:C14.280.383 378:D08.811.913.696.620.682.700.755|ES| 19:1 102:1 303:1 304:1 383:1 615:1 616:1 2094:1 2095:1
1 	|BT| (S (NP (NN miR-221)) (VP (VBZ Mediates) (NP (NNP Chemoresistance) (NNP Esophageal) (NNP Adenocarcinoma) (NNP Direct) (NN Targeting) (NN DKK2) (NN Expression)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700|ES| 19:1 140:1 316:1 1215:1 2096:1 2097:1 2098:1 2099:1 2100:1 2101:1
1 	|BT| (S (NP (NN miR-490-3p)) (VP (VBD exerted) (NP (NP (NN growth)) (: -) (NP (NP (JJ metastasis-suppressive) (NN effect) (JJ gastric) (NN cancer) (NN cell)) (VP (ADVP (RB directly)) (VBG targeting) (NP (NP (NN SMARCD1)) (, ,) (NP (NP (NN SWItch/Sucrose) (NN NonFermentable)) (PRN (-LRB- -LRB-) (NP (NN SWI/SNF)) (-RRB- -RRB-))) (NP (NN chromatin) (NN remodeling) (NN complex) (NN subunit)))))))) |ET| |BS|41:A11 45:G07.700.320.249 113:C04.697.650 582:D09.698.629.305.770 583:D12.776.813|ES| 2:1 10:1 14:1 18:1 19:1 75:1 86:1 94:1 608:1 616:1 621:1 695:1 1346:1 2102:1 2103:1 2104:1 2105:1 2106:1 2107:1 2108:1 2109:1 2110:1
1 	|BT| (S (NP (NN miRNA-548p)) (VP (VBZ suppresses) (NP (NP (NN hepatitis) (NN B) (NN virus) (NN X) (NN protein)) (VP (VBN associated) (NP (NP (JJ hepatocellular) (NN carcinoma)) (VP (VBG downregulating) (NP (NN oncoprotein) (NN hepatitis) (NN B) (JJ x-interacting) (NN protein)))))))) |ET| |BS|104:C04.557.470.200.025.255 184:D13.150.650.319 584:D12.776.624.664|ES| 4:1 19:1 169:1 303:1 304:1 686:1 763:1 929:1 1422:1 2048:1 2065:1 2111:1 2112:1 2113:1
1 	|BT| (FRAG (PP (JJ Molecular) (S (VP (VBG targeting) (NP (NP (NP (NN GSK3beta) (NN overexpression) (NN GSK3beta) (JJ dominant-negative) (NN mutant)) (, ,) (NP (JJ acute-silencing) (NN GSK3beta) (NN RNA) (NN interference)) (, ,)) (VBN reproduced) (NN induction)) (NP (ADJP (RB transcriptionally) (JJ active)) (NP (NN p53) (JJ colorectal) (NN cancer) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 156:G05.355.315.203.374.790|ES| 2:1 12:1 17:1 18:1 19:1 94:1 152:1 197:1 515:1 516:1 616:1 736:1 811:1 1854:1 1894:1 2114:1 2115:1 2116:1 2117:1
1 	|BT| (S (S (NP (JJS Most) (JJ human) (JJ colorectal) (NN cancer)) (VP (VB arise) (NP (NN accumulation) (NN series) (JJ genetic) (NN alteration) (NN point) (NN mutation)) (PP (IN within) (NP (JJ Ki-ras) (NN p53) (NN gene))))) (, ,) (NP (NN chemical) (NN carcinogen)) (VP (MD may) (VP (VBN implicated) (NP (NN event) (ADJP (RB still) (JJ unidentified)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100 438:G05.365.590.675|ES| 2:1 9:1 12:1 17:1 18:1 19:1 34:1 36:1 205:1 491:1 776:1 864:1 951:1 977:1 1807:1 2118:1 2119:1 2120:1 2121:1 2122:1 2123:1 2124:1 2125:1 2126:1
1 	|BT| (S (S (NP (NN Mouse) (NN strain)) (VP (VBD disrupted) (S (NP (NP (NN sPLA)) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (NN gene) (JJ susceptible) (NN Min) (NN phenotype)) (VP (VBP develop) (NP (JJ numerous) (JJ intestinal) (NN polyp))))) (, ,)) (IN whereas) (S (NP (NP (NN mouse) (JJ normal) (NN sPLA)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (VP (VBP develop) (NP (JJ limited) (NN number) (NN polyp))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 80:G05.695 192:D08.811.277.352.100.680.750.937.750 193:C23.300.825.411 444:C23.300.825|ES| 2:1 9:1 10:1 14:1 19:1 52:1 109:1 118:1 148:1 236:1 372:1 646:1 647:1 648:1 650:1 899:1 2039:1 2127:1 2128:1 2129:1 2130:1 2131:1
1 	|BT| (NP (NP (NNS Mutations) (NP (NP (NN APC) (NN gene) (JJ responsible) (JJ familial) (JJ adenomatous) (NN polyposis)) (PRN (-LRB- -LRB-) (NP (NN FAP)) (-RRB- -RRB-))) (NN majority) (JJ sporadic) (JJ colorectal) (NN cancer))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 18:G05.365.590 21:G05.360.340.024.340.375.249.050|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 57:1 58:1 198:1 725:1 854:1 1410:1 2132:1 2133:1
1 	|BT| (NP (NP (NNS Mutations)) (NP (NP (NP (JJ human) (NN DNA) (NN mismatch) (NN repair)) (PRN (-LRB- -LRB-) (NP (NN MMR)) (-RRB- -RRB-))) (NP (NP (NP (NN gene) (NN MLH1) (VBN associated) (JJ hereditary) (JJ nonpolyposis) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NP (NNP Lynch) (NN syndrome)) (, ,) (NP (NN HNPCC))) (-RRB- -RRB-))) (NP (JJ significant) (NN proportion) (JJ sporadic) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 174:G02.111.087.219.220 524:C04.588.274.476.411.307.190|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 36:1 135:1 169:1 513:1 584:1 666:1 723:1 725:1 1294:1 1410:1 1845:1 1846:1 1940:1 2134:1 2135:1 2136:1
1 	|BT| (NP (NNS Mutations) (NP (NP (NN APC) (NN gene) (NN play) (JJ critical) (NN role)) (JJ sporadic) (JJ familial) (NN form) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 18:G05.365.590 21:G05.360.340.024.340.375.249.050 44:F01.829.263 79:I03.450.642.693 189:V02.460|ES| 9:1 11:1 17:1 18:1 19:1 31:1 238:1 630:1 725:1 825:1 854:1 1410:1
1 	|BT| (S (NP (NN NAC1)) (VP (VBZ modulates) (NP (NP (NN sensitivity) (JJ ovarian) (NN cancer) (NN cell) (NN cisplatin)) (VP (VBG altering) (NP (JJ HMGB1-mediated) (JJ autophagic) (NN response)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 390:G04.299.139.399 498:D01.210.375 585:D12.644.276.087.371|ES| 18:1 19:1 94:1 494:1 606:1 607:1 1761:1 1763:1 2137:1 2138:1 2139:1 2140:1
1 	|BT| (S (NP (NN Number) (NN size) (JJ intestinal) (NN tumor)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NN mouse) (NN bearing) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN PTEN) (NN mutation)))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 102:C04.588.274.476.411 455:B01.050.150.900.649.147.890|ES| 7:1 10:1 11:1 14:1 19:1 34:1 47:1 52:1 57:1 58:1 59:1 109:1 124:1 1584:1 1936:1 2141:1 2142:1
1 	|BT| (S (NP (JJ Oncogenic) (NN mutation) (NN K-ras) (NN gene)) (VP (VBP occur) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (NP (JJ human) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100|ES| 9:1 17:1 18:1 19:1 34:1 36:1 368:1 369:1 1121:1 1843:1 2044:1 2143:1
1 	|BT| (S (NP (NP (CD One) (JJ common) (JJ rate-limiting) (NN mutation)) (JJ human) (NN CRC)) (VP (VBZ occurs) (NP (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene)))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 194:G05.355.044.250.750|ES| 9:1 10:1 11:1 14:1 19:1 34:1 36:1 57:1 58:1 59:1 245:1 654:1 655:1 656:1 657:1
1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (NP (JJ important) (NP (NN role) (NN beta2-AR/STAT3/miR) (CD -373) (NN signaling) (NN transformation) (JJ gastric) (NN cancer) (NN cell))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 41:A11 69:G02.111.087.800 82:D12.644.360.024.342.300|ES| 18:1 19:1 31:1 86:1 94:1 195:1 658:1 793:1 796:1 902:1 1384:1 2144:1
1 	|BT| (S (NP (PRP$ Our) (NN finding) (NN support) (JJ mir-660) (NN act) (NN tumor) (NN suppressor) (NN miRNA)) (VP (VBP suggest) (NP (NN replacement) (JJ mir-660) (JJ new) (JJ therapeutic) (NN approach) (NN p53) (JJ wild-type) (NN lung) (NN cancer) (NN treatment)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 52:E02 81:E02.095.465.425.400.330.050.400 181:E04.936.494 184:D13.150.650.319 206:G05.360.340.024.340.375.249 275:C23.888 375:Z01.639.100|ES| 7:1 8:1 12:1 18:1 19:1 246:1 328:1 373:1 541:1 546:1 614:1 658:1 700:1 712:1 796:1 840:1 911:1 927:1 1364:1
1 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (SBAR (S (NP (NN JNK/PTEN) (NN NF-kappaB/PTEN) (NN pathway)) (VP (VBP play) (NP (JJ critical) (NP (NN role) (JJ normal) (NP (JJ intestinal) (NN homeostasis) (NN colon) (NN carcinogenesis))))))))) |ET| |BS|15:F01.829.316.616 33:C04.697.098 46:A03.556.124.526.356 47:A03.556.124 79:I03.450.642.693 152:G07.700.345 210:D12.776.260.600|ES| 19:1 31:1 109:1 113:1 118:1 207:1 238:1 383:1 500:1 658:1 796:1 825:1 927:1 2145:1 2146:1
1 	|BT| (S (NP (NP (PRP$ Our) (VBN integrated) (NN microRNA)) (VP (VBG profiling) (NP (NN approach)))) (VP (VBD identified) (S (NP (NN miR-195-5p)) (ADVP (RB independently)) (VP (VBN associated) (NP (NN prognosis) (NN CRC)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 163:E01.789 184:D13.150.650.319|ES| 19:1 169:1 245:1 271:1 544:1 623:1 658:1 857:1 911:1 2147:1 2148:1 2149:1
1 	|BT| (S (NP (PRP$ Our) (JJ recent) (NN study)) (VP (VB establish) (NP (JJ oncogenic) (NN role) (NP (NP (NNP LSF) (JJ Hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 104:C04.557.470.200.025.255 279:D27.888.569.100|ES| 10:1 14:1 19:1 31:1 131:1 220:1 304:1 441:1 658:1 659:1 953:1 2150:1 2151:1
